From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!ihnp4.ucsd.edu!newsfeed.berkeley.edu!newsfeed.nyu.edu!isdnet!news1.isdnet.net!usenet From: "Asher" Newsgroups: bionet.immunology Subject: Re: Brain lesions Date: Fri, 2 Oct 1998 12:01:48 +0200 Lines: 20 Message-ID: <6v285s$3hi$1@news2.isdnet.net> References: <19980929125317.10309.00003490@ng16.aol.com> NNTP-Posting-Host: sophia2-2.isdnet.net X-Newsreader: Microsoft Outlook Express 4.72.2106.4 X-MimeOLE: Produced By Microsoft MimeOLE V4.72.2106.4 We just sent you a message, Please accept our best encouragements Best regards biocareworld PASSAUTO a écrit dans le message <19980929125317.10309.00003490@ng16.aol.com>... > >Looking for information regarding multiple brain lesions related to autoimmune >disorders. > >Any help greatly appreciated. From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!agate!newsfeed.berkeley.edu!sunqbc.risq.qc.ca!isdnet!news1.isdnet.net!usenet From: "Asher" Newsgroups: bionet.immunology Subject: Re: Brain lesions Date: Fri, 2 Oct 1998 11:54:49 +0200 Lines: 16 Message-ID: <6v27op$3e5$1@news2.isdnet.net> References: <19980929125317.10309.00003490@ng16.aol.com> NNTP-Posting-Host: sophia2-2.isdnet.net X-Newsreader: Microsoft Outlook Express 4.72.2106.4 X-MimeOLE: Produced By Microsoft MimeOLE V4.72.2106.4 Good morning,dear PASSAUTO We can really help you, if you send us further informations, thanks to the" TRADITIONAL CHINESE DIAGNOSTIC" and the "CHINESE FARMACOPEE". See our Web site: http://biocareworld-riviera.com PASSAUTO a écrit dans le message <19980929125317.10309.00003490@ng16.aol.com>... > >Looking for information regarding multiple brain lesions related to autoimmune >disorders. > >Any help greatly appreciated. From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!logbridge.uoregon.edu!news-peer.gip.net!news.gsl.net!gip.net!news.idt.net!netnews.com!newspeer.monmouth.com!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: fm.raaphorst@azvu.nl Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: HIV/AIDS and the Perth Group. Was:"AIDS Treatment News"... Date: Fri, 02 Oct 1998 08:34:33 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 53 Message-ID: <6v236p$gls$1@nnrp1.dejanews.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> <3614289A.5A26@ix.netcom.com> NNTP-Posting-Host: 130.37.210.210 X-Article-Creation-Date: Fri Oct 02 08:34:33 1998 GMT X-Http-User-Agent: Mozilla/4.0 (compatible; MSIE 4.01; Windows 95) X-Http-Proxy: 1.1 x13.dejanews.com:80 (Squid/1.1.22) for client 130.37.210.210 Xref: biosci bionet.immunology:14789 bionet.molbio.hiv:4954 In article <3614289A.5A26@ix.netcom.com>, todd33@ix.netcom.com wrote: > Leonard Pattenden wrote: > > > I have shown the > > Virology 230 papers were not about "non-isolation" or it's > > "impossibility". It was about microvesicle contamination. > > Leonard, maybe you can help me with a question I've never gotten > a good answer to. With all this microvesicle contamination that > comes along with "HIV" when it is purified on sucrose gradients > (at least until recently, when a paper you know about found that > protease treatment of the gradient fraction containing "HIV" > could remove up to 95% of the contaminants, mostly actin), how > did Dr Gallo generate antibodies to "HIV" in a rabbit back in > 1984 in the _Science_ papers that made him so famous? There is > no information about what was used as an antigen, but I think > it is probably safe to assume that it was density gradient > purified material, which as one of those recent _Virology_ papers > shows, is at best half "HIV" and half cellular proteins. The > coomassie stained PAGE in this paper of the gradient purified > material is not very impressive either, as far as using this as > an antigen -- there are proteins that run the entire gamut of > molecular weights! > > How could he claim that the antibodies from the rabbit were > specific for "HIV" given that the antigen could not possibly > have been pure "HIV" and that apparently, at that time, no one > had really investigated methods of trying to further purfiy > "HIV"? > It doesn't matter at all whether the vaccination happens with a pure isolate - it all depends on the selection method that's used to characterize the resulting antibodies. Immunization with something that 'is at best half "HIV"', and the rest consisting of cellular material from a human cell line, will work just fine. Of course you'll generate a lot of B-cell lines producing antibodies specific for common, cellular, proteins. But in addition there will be B-cell lines that produce an antibody against HIV-proteins. Even if these proteins haven't been characterized by molecular cloning, you can identify the antibodies that recognize them. For instance, you screen the collection of antibodies you generated against uninfected cells and infected cells. Immunofluorescence will do the trick. Antibodies specific for common cellular antigens will bind to both infected and uninfected cell lines. Antibodies specific for an HIV-encoded protein, for instance the envelope proteins, will only bind to the infected cell lines. Frank Raaphorst -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.direct.ca!news.uunet.ca!news1.ottawa.cyberus.ca!news.cyberus.ca!not-for-mail From: "David Smith" Newsgroups: bionet.immunology Subject: PSA antibodies Date: 1 Oct 1998 12:53:06 GMT Organization: Pharmacon Research Inc. Lines: 1 Message-ID: <01bded5b$24781be0$c054c3d1@default> NNTP-Posting-Host: ip192.ts4.mn.dialup.ottawa.cyberus.ca X-Trace: news1.ottawa.cyberus.ca 907246386 14035 209.195.84.192 (1 Oct 1998 12:53:06 GMT) X-Complaints-To: support@cyberus.ca NNTP-Posting-Date: 1 Oct 1998 12:53:06 GMT X-Newsreader: Microsoft Internet News 4.70.1162 I am looking for a source of anti-PSA antibody for use in an ELISA . From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Message-ID: <3614820C.15C2@jps.net> Date: Fri, 02 Oct 1998 00:34:36 -0700 From: "Charles P. McCarthy, P.M.D. (Hon)" Reply-To: Pandoc@jps.net Organization: Bio International X-Mailer: Mozilla 3.01Gold (Win16; I) MIME-Version: 1.0 Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: A Little Pussy for Todd References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> <3614289A.5A26@ix.netcom.com> Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit NNTP-Posting-Host: 209.239.193.72 X-NNTP-Posting-Host: 209.239.193.72 Lines: 39 X-NNTP-Posting-Host: 209.63.114.134 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.cwix.com!207.0.56.122!news.eli.net!blushng.jps.net!209.239.193.72 Xref: biosci bionet.immunology:14787 bionet.molbio.hiv:4953 Serological responses of cats to feline immunodeficiency virus. Hosie MJ; Jarrett O Department of Veterinary Pathology, University of Glasgow, UK. AIDS, 1990 Mar, 4:3, 215-20 The proteins of feline immunodeficiency virus (FIV) were identified by sodium dodecylsulphate poly-acrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. Purified [35S]methionine/cysteine- labelled virus contained proteins of Mr 120, 24, 17, and 10kD, of which the most prominent were p24 and p17, and minor components of 62, 54, 52, 41 and 32kD. Sera from FIV-infected cats precipitated two glycoproteins (gp) of Mr 120kD (gp120) and 41kD (gp41) from lysates of [14C]glucosamine-labelled infected cells. Purified virus contained very little or no detectable glycoproteins. The serological response to individual viral proteins was followed in experimentally infected cats by immunoblotting. Since purified virus was a poor source of gp120, a method using FIV-infected cell lysates was developed. Cats produced antibodies to gp120, p55, p24 and p17. (The p55 was presumed to be a precursor of p24 and p17.) Following infection, antibodies developed first to p24 and subsequently to p17, p55 and gp120. Sera from cats infected with three separate isolates of FIV, two from the UK and one from the USA, had cross-reacting antibodies to all of these viral proteins. The criteria for identification of seropositive cats were defined. The minimum requirement for a positive immunoblot was antibody to gp120 or to at least three core proteins (p55, p24 and p17). Comparison of two commercial enzyme-linked immunosorbent assay (ELISA) kits and immunoblotting indicated that false-positive results occurred as a result of non-specific reactions in the ELISA systems. From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.corridex.com!netnews.com!newsfeed.enteract.com!ix.netcom.com!news From: Todd Miller Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: HIV/AIDS and the Perth Group. Was:"AIDS Treatment News"... Date: Thu, 01 Oct 1998 21:12:58 -0400 Organization: ICGNetcom Lines: 30 Message-ID: <3614289A.5A26@ix.netcom.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> Reply-To: todd33@ix.netcom.com NNTP-Posting-Host: mia-fl1-26.ix.netcom.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-NETCOM-Date: Thu Oct 01 6:13:38 PM PDT 1998 X-Mailer: Mozilla 3.0C-NC320 (Win95; I) Xref: biosci bionet.immunology:14783 bionet.molbio.hiv:4950 Leonard Pattenden wrote: > I have shown the > Virology 230 papers were not about "non-isolation" or it's > "impossibility". It was about microvesicle contamination. Leonard, maybe you can help me with a question I've never gotten a good answer to. With all this microvesicle contamination that comes along with "HIV" when it is purified on sucrose gradients (at least until recently, when a paper you know about found that protease treatment of the gradient fraction containing "HIV" could remove up to 95% of the contaminants, mostly actin), how did Dr Gallo generate antibodies to "HIV" in a rabbit back in 1984 in the _Science_ papers that made him so famous? There is no information about what was used as an antigen, but I think it is probably safe to assume that it was density gradient purified material, which as one of those recent _Virology_ papers shows, is at best half "HIV" and half cellular proteins. The coomassie stained PAGE in this paper of the gradient purified material is not very impressive either, as far as using this as an antigen -- there are proteins that run the entire gamut of molecular weights! How could he claim that the antibodies from the rabbit were specific for "HIV" given that the antigen could not possibly have been pure "HIV" and that apparently, at that time, no one had really investigated methods of trying to further purfiy "HIV"? Todd Miller, PhD From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!howland.erols.net!newsfeed.cwix.com!204.238.120.130!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: asheat@my-dejanews.com Newsgroups: bionet.immunology Subject: TNF production from THP-1 Date: Fri, 02 Oct 1998 15:09:59 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 8 Message-ID: <6v2qc7$c3i$1@nnrp1.dejanews.com> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Fri Oct 02 15:09:59 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x13.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 Dear Members Iam finding some difficulty in getting TNF from THP-1 after stimulating with LPS 10 ng-10,000 ng/ml(ELISA and Bioassay). Please help me in this matter. What might be the reason for this failure. -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!rill.news.pipex.net!pipex!main.de.uu.net!news-reader.dortmund.de.uu.net!not-for-mail From: "Susanne Holthausen" Newsgroups: bionet.immunology Subject: C5a und Thrombozyten Date: Fri, 2 Oct 1998 15:13:46 +0200 Organization: UUNET Deutschland GmbH, Dortmund, Germany Lines: 9 Message-ID: <6v2jg4$9k0$1@goof.de.uu.net> NNTP-Posting-Host: 149.228.247.15 X-Newsreader: Microsoft Outlook Express 4.72.3110.1 X-MimeOLE: Produced By Microsoft MimeOLE V4.72.3110.3 Ich beschäftige mich mit der Komplementaktivierung bei Kindern mit soliden Tumoren während IL-2 Therapie mit Kapillarlecksyndrom. Wer kann mir allgemein über Zusammenhänge von C5a und Thrombozyten berichten? From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.direct.ca!news.u.washington.edu!fae2xx.biostat.washington.edu!user From: marnix@u.washington.edu (Marnix L. Bosch) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: Fri, 02 Oct 1998 14:46:51 -0700 Organization: UW Lines: 25 Message-ID: References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> NNTP-Posting-Host: fae2xx.biostat.washington.edu X-Trace: nntp4.u.washington.edu 907364725 32432 (None) 140.142.17.39 X-Complaints-To: help@cac.washington.edu Xref: biosci bionet.immunology:14796 bionet.molbio.hiv:4958 In article <361545cd.83282293@netnews.worldnet.att.net>, johnburgin@worldnet.att.net wrote: > >If you knew anything about the field that you blather on about, > >you would know that proteases are virtually never prescribed without > >*2* drugs from AZT's class (nucleoside analogue reverse transcriptase > >inhibitors) The most commonly prescribed protease-containing regimens > >consist of AZT, 3TC, and a protease. That is one thing I have never > >seen any "dissident" be able to explain. If AZT is so toxic, how come > >combining it with another drug in it's class, and a protease causes > >death rates to drop in clinical endpoint trials? > The short answer or the long one? I prefer the short. Less AZT > combined with anything else in the PI category means less toxicity. > Why is that so confusing? Am I missing something, do you contend that > the same amounts of AZT are given "with" PI "therapy" as "recommended" > alone? There you have it, a "dissident "explains".jb Thanks for this testimony of ignorance. I'll give you a chance to correct it though. Please post data showing that AZT in combo therapy is given in lower doses than used in monotherapy. If those data show the doses are no different, then please address the question again. Marnix Bosch From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!nntp.cs.ubc.ca!newsfeed.direct.ca!wn3feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 2 Oct 1998 23:00:56 GMT Organization: AT&T WorldNet Services Lines: 34 Message-ID: <36155a63.88553199@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> NNTP-Posting-Host: 12.65.209.74 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14797 bionet.molbio.hiv:4959 On Fri, 02 Oct 1998 14:46:51 -0700, marnix@u.washington.edu (Marnix L. Bosch) wrote: >In article <361545cd.83282293@netnews.worldnet.att.net>, >johnburgin@worldnet.att.net wrote: > > >> >If you knew anything about the field that you blather on about, >> >you would know that proteases are virtually never prescribed without >> >*2* drugs from AZT's class (nucleoside analogue reverse transcriptase >> >inhibitors) The most commonly prescribed protease-containing regimens >> >consist of AZT, 3TC, and a protease. That is one thing I have never >> >seen any "dissident" be able to explain. If AZT is so toxic, how come >> >combining it with another drug in it's class, and a protease causes >> >death rates to drop in clinical endpoint trials? > >> The short answer or the long one? I prefer the short. Less AZT >> combined with anything else in the PI category means less toxicity. >> Why is that so confusing? Am I missing something, do you contend that >> the same amounts of AZT are given "with" PI "therapy" as "recommended" >> alone? There you have it, a "dissident "explains".jb > >Thanks for this testimony of ignorance. I'll give you a chance to correct >it though. Please post data showing that AZT in combo therapy is given in >lower doses than used in monotherapy. If those data show the doses are no >different, then please address the question again. Marnix, people are living longer without the dosages of AZT as before the era of the PI's for "AIDS" therapy. Just check out the declining death rates, your choice, CDC, NIH, whatever. Answer the question, are AZT dosages less in combined therapy than when AZT was prescribed alone? Can't handle this one, Herr Marnix? jb > >Marnix Bosch From owner-immunology@net.bio.net Thu Oct 01 23:00:00 1998 Path: biosci!news.stanford.edu!nntp.cs.ubc.ca!newsfeed.direct.ca!wn4feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 2 Oct 1998 21:33:48 GMT Organization: AT&T WorldNet Services Lines: 123 Message-ID: <361545cd.83282293@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> NNTP-Posting-Host: 12.65.211.197 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14795 bionet.molbio.hiv:4957 On 1 Oct 1998 17:14:56 GMT, carlton@walleye.ccbr.umn.edu (Carlton Hogan) wrote: >In article <3611441e.663553911@netnews.worldnet.att.net>, > wrote: >>On 28 Sep 1998 16:48:29 GMT, carlton@walleye.ccbr.umn.edu (Carlton >>Hogan) wrote: >> >>>In article <360c04a9.319577014@netnews.worldnet.att.net>, >>> wrote: >>>>On 25 Sep 1998 20:52:04 GMT, carlton@walleye.ccbr.umn.edu (Carlton >>>>Hogan) wrote: >>>> >>>>>In article <360bfe32.317922269@netnews.worldnet.att.net>, >>>>> wrote: >>>>>>On 25 Sep 1998 16:40:29 GMT, carlton@walleye.ccbr.umn.edu (Carlton >>>>>>Hogan) wrote: >>>>>> >>>>>>>>johnburgin@worldnet.att.net wrote: >>>>>>>> >>>>>>>> >>>>>>>>>I have spoken to AIDS patients that I have treated >>>>>>>>>that don't know why they are taking chemotherapy medication. >>>>>>> >>>>>>>Please name a prescribed drug that is *not* chemotherapy. If you treat >>>>>>>patients, I will eat my hat. >>>>>>Are you hungry? Dose makes the poison, I said that before. Aspirin, >>>>>>is a chemotherapy drug. Now, just be sure that our laiety isn't >>>>>>confused, and without any Clintonesque problems with defining terms, >>>>>>ask any person who has been through "chemotherapy" what a chemotherapy >>>>>>drug is. You won't need to put stars around their responses. jb >>>>> >>>>>No stars necessary. Sure, the poison is in the dose: enough salt >>>>>or water can kill somebody. Yet we don't advise against salt or >>>>>water. I'll say it again, slowly so that you can grasp it: >>>>>dissidents commonly use the term "chemotherapy" when talking >>>>>about HIV antivirals specifically and intentionally to confuse >>>>>people by making them think that cytotoxic cancer chemotherapy >>> >>>>well, imagine how confused those "people" must be when you, you dumb >>>>ass, cannot even understand that AZT is a DNA chain terminator. >>> >>>Actually, although some low-level interference may occur, and cause >>>side-effects, AZT was initially chosen as a potential HIV therapy >>>because it is fairly specific, with much higher viral inhibition >>>that cellular. The data is in the AZT package insert and PDR >>>entry. If you have contrary data, please post it. >>> >>>> That >>>>was probably the most ignorant statement that you have made thus far. >>>>>is being discussed. Although AZT was screened as a candidate >>>>>molecule for anti-neoplastic drugs, it failed, in great degree >>>>>because it was not cytotoxic enough >>>>Oh contrare, it was cytotoxic enough to be dc'd as a chemotherapy drug >>>>when first developed at the Detroit Cancer Foundation, 1964, Jerome >>>>Horwitz, head of the lab, because more lab rats DIED with AZT than >>>>without it when treated for tumors. I guess that's not factual enough >>>>for you either, eh? jb >>> >>>In the context of anti-neoplastics, an increased death rate does >>>*not* neccesarily reflect cytotoxicity. A higher death rate can mean >>>dozens of thing, ranging from just an ineffective treatment, to >>>a wide range of toxicities that are not all cytotoxic. If you have >>>evidence that 1. the mice died of cytotoxic effects, and 2. the dosages >>>were (weight adjusted) roughly equivalent to prescribed human dosages >>>please post them. >>> >>>Remember: you brought up up the "poison is in the dose" argument. >>>There are many pharaceutical compounds, and even food stuffs that >>>are well tolerated in humans, yet will kill laboratory rates in >>>high enough dosages. >>> >>>If there is any data that supports your claims, I am eager to see it. >> >>The package insert, now that's interesting. I'm really getting >>confused by the argument that you are presenting. You keep trying to >>protect the assumption that AZT is not an immune depressive chemical >>but assert that it is not a good drug for the treatment of AIDS(Why >>isn't it, I mean, if it's so safe and so specific?) > >I never said it was totally safe. AZT is fairly toxic. But it is >not immunesuppressive in any way that resembles AIDS. The chief >problem is that the virus mutates so frequently, it quickly escapes >AZT monotherapy. However, in combination with a protease, or other >nucleosides, AZT can be part of a very effective, and relatively >enduring regimen. > >>. I am, and have >>been, asserting that AZT is a bad drug for the treatment of anything >>except those wishing to kill every living cell in their body, which, >>it does quite well in the proper amounts and if consumed for a long >>enough period of time. > >Evidence? > > Protease inhibitors do not appear to be as >>toxic from the latest info that I have seen. > >If you knew anything about the field that you blather on about, >you would know that proteases are virtually never prescribed without >*2* drugs from AZT's class (nucleoside analogue reverse transcriptase >inhibitors) The most commonly prescribed protease-containing regimens >consist of AZT, 3TC, and a protease. That is one thing I have never >seen any "dissident" be able to explain. If AZT is so toxic, how come >combining it with another drug in it's class, and a protease causes >death rates to drop in clinical endpoint trials? The short answer or the long one? I prefer the short. Less AZT combined with anything else in the PI category means less toxicity. Why is that so confusing? Am I missing something, do you contend that the same amounts of AZT are given "with" PI "therapy" as "recommended" alone? There you have it, a "dissident "explains".jb There are now at least >a dozen well-conducted, randomized trials that show that combination >therapy reduces morbidity and mortality compared to AZT montherapy. > >> Maybe if you tried >>something a little less toxic, like a placebo, the humps and Crix >>bellys would disappear also. > >Is that a lame attempt at a personal attack? > >Carlton From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!howland.erols.net!panix!news.columbia.edu!ciao.cc.columbia.edu!it8 From: Ilya Trakht Newsgroups: bionet.immunology Subject: postdoctoral at columbia university Date: Sat, 3 Oct 1998 12:47:19 -0400 Organization: Columbia University Lines: 23 Message-ID: NNTP-Posting-Host: ciao.cc.columbia.edu Mime-Version: 1.0 Content-Type: TEXT/PLAIN; charset=US-ASCII Postdoctoral Position available now for recent graduates trained in cell biology, molecular biology and immunology, with interests in developing totally human monoclonal antibodies to cancer-associated antigens and infections agents with a potential for application in clinical medicine. An extensive expetise in cell culture, immunoassays, immunohistochemistry, molecular biology techniques is mostly preferred. Interested individuals should forward Curriculum Vitae, description research experience, brief statement of research interests and three letters of recomendation to: Dr. Ilya Trakht Department of Medicine, Columbia University 650W, 168th Street, BB-1011 New York, NY 10032 E-mail: it8@columbia.edu From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!news-peer.sprintlink.net!news.sprintlink.net!wn3feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 3 Oct 1998 18:16:40 GMT Organization: AT&T WorldNet Services Lines: 46 Message-ID: <361669aa.158010084@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v55as$8t4$1@nnrp1.dejanews.com> NNTP-Posting-Host: 12.65.209.185 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14806 bionet.molbio.hiv:4966 On Sat, 03 Oct 1998 12:29:21 GMT, f.raaphorst@worldonline.nl wrote: >In article <36155a63.88553199@netnews.worldnet.att.net>, > johnburgin@worldnet.att.net wrote: >> On Fri, 02 Oct 1998 14:46:51 -0700, marnix@u.washington.edu (Marnix L. >> Bosch) wrote: >> >> >In article <361545cd.83282293@netnews.worldnet.att.net>, >> >johnburgin@worldnet.att.net wrote: >> > >> > >> >> >If you knew anything about the field that you blather on about, >> >> >you would know that proteases are virtually never prescribed without >> >> >*2* drugs from AZT's class (nucleoside analogue reverse transcriptase >> >> >inhibitors) The most commonly prescribed protease-containing regimens >> >> >consist of AZT, 3TC, and a protease. That is one thing I have never >> >> >seen any "dissident" be able to explain. If AZT is so toxic, how come >> >> >combining it with another drug in it's class, and a protease causes >> >> >death rates to drop in clinical endpoint trials? >> > >> >> The short answer or the long one? I prefer the short. Less AZT >> >> combined with anything else in the PI category means less toxicity. >> >> Why is that so confusing? Am I missing something, do you contend that >> >> the same amounts of AZT are given "with" PI "therapy" as "recommended" >> >> alone? There you have it, a "dissident "explains".jb >> > >> >Thanks for this testimony of ignorance. I'll give you a chance to correct >> >it though. Please post data showing that AZT in combo therapy is given in >> >lower doses than used in monotherapy. If those data show the doses are no >> >different, then please address the question again. >> Marnix, people are living longer without the dosages of AZT as before >> the era of the PI's for "AIDS" therapy. Just check out the declining >> death rates, your choice, CDC, NIH, whatever. Answer the question, >> are AZT dosages less in combined therapy than when AZT was prescribed >> alone? Can't handle this one, Herr Marnix? jb > >Just answer the question jb, not this evasive stuff. >Come on, we're waiting. you first. It's the same kind of question, a trap. All you have to do is answer "yes or no". jb > >Frank Raaphorst > >-----------== Posted via Deja News, The Discussion Network ==---------- >http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!news.maxwell.syr.edu!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: f.raaphorst@worldonline.nl Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: HIV/AIDS and the Perth Group. Was:"AIDS Treatment News"... Date: Sat, 03 Oct 1998 15:56:31 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 84 Message-ID: <6v5hfe$d92$1@nnrp1.dejanews.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> <3614289A.5A26@ix.netcom.com> <6v236p$gls$1@nnrp1.dejanews.com> <361626C9.1FF8@ix.netcom.com> NNTP-Posting-Host: 195.241.227.209 X-Article-Creation-Date: Sat Oct 03 15:56:31 1998 GMT X-Http-User-Agent: Mozilla/4.03 [nl] (Win95; I) X-Http-Proxy: 1.0 x1.dejanews.com:80 (Squid/1.1.22) for client 195.241.227.209 Xref: biosci bionet.immunology:14802 bionet.molbio.hiv:4964 In article <361626C9.1FF8@ix.netcom.com>, todd33@ix.netcom.com wrote: > fm.raaphorst@azvu.nl wrote: > > > > In article <3614289A.5A26@ix.netcom.com>, > > todd33@ix.netcom.com wrote: > > > > How could he claim that the antibodies from the rabbit were > > > specific for "HIV" given that the antigen could not possibly > > > have been pure "HIV" and that apparently, at that time, no one > > > had really investigated methods of trying to further purfiy > > > "HIV"? > > > > > > > It doesn't matter at all whether the vaccination happens with a pure > > isolate - it all depends on the selection method that's used to > > characterize the resulting antibodies. > > There was no information about this in the Gallo papers, but I > agree this is one way to deal with the problem. > > > Immunization with something that 'is at best half "HIV"', and the > > rest consisting of cellular material from a human cell line, will > > work just fine. Of course you'll generate a lot of B-cell lines > > producing antibodies specific for common, cellular, proteins. But > > in addition there will be B-cell lines that produce an antibody > > against HIV-proteins. Even if these proteins haven't been > > characterized by molecular cloning, you can identify the antibodies > > that recognize them. For instance, you screen the collection of > > antibodies you generated against uninfected cells and infected > > cells. Immunofluorescence will do the trick. Antibodies specific > > for common cellular antigens will bind to both infected and > > uninfected cell lines. Antibodies specific for an HIV-encoded > > protein, for instance the envelope proteins, will only bind to > > the infected cell lines. > > This could be done, although some experiments would have to be > performed to show that antigens unique to the infected cell line > were truly viral, and not some endogenous protein induced by the > experiment/infection. Granted, but we're not talking about a single protein here. Would you really expect an epidemic of people mounting an immunological response to a multitude of 'self' antigens? I think the size of the response, and the repeated isolation of typical retroviral genes and proteins points to an infection with a retrovirus. I guess there are also methods to use such > Western blots preparatively, so that the antibodies binding to > specifically induced antigens could be purified. The following > link shows the proteins that are purified from 2 different lines > of infected cells (lanes B and C), compared to uninfected cells > (lane A). I wouldn't want the task of trying to purify polyclonal > antibodies from a rabbit that were specific for "infected" vs > "uninfected" cells in this situation. Why not? It's quite simple if the pathogen has been isolated and its genes have been cloned (which to my mind has been done). One way to screen the antibodies would be through phage-display libraries, and even such experiments have been done. Gallo does show the > blots for uninfected vs infected, but selects only serum that > was shown to be "positive" on infected at a 1:100 dilution, > and then instead uses a 1:500 dilution for the blots with > infected and uninfected extracts. Frankly, even in the original > _Science_ paper, it is extremely difficult to see anything, > probably because of the highly diluted antibody. > > http://www.virusmyth.com/aids/perthgroup/geneva/slide23.htm > > Thanks for your response Frank. > > Todd Miller I still fail to grasp why the shortcomings of the original Gallo paper refute the current results from independent labs all over the world. have a good weekend, Frank -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!ihnp4.ucsd.edu!sdd.hp.com!usc!howland.erols.net!news-nyc.telia.net!news.maxwell.syr.edu!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: f.raaphorst@worldonline.nl Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: Sat, 03 Oct 1998 12:29:21 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 41 Message-ID: <6v55as$8t4$1@nnrp1.dejanews.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> NNTP-Posting-Host: 195.241.227.47 X-Article-Creation-Date: Sat Oct 03 12:29:21 1998 GMT X-Http-User-Agent: Mozilla/4.03 [nl] (Win95; I) X-Http-Proxy: 1.0 x6.dejanews.com:80 (Squid/1.1.22) for client 195.241.227.47 Xref: biosci bionet.immunology:14800 bionet.molbio.hiv:4961 In article <36155a63.88553199@netnews.worldnet.att.net>, johnburgin@worldnet.att.net wrote: > On Fri, 02 Oct 1998 14:46:51 -0700, marnix@u.washington.edu (Marnix L. > Bosch) wrote: > > >In article <361545cd.83282293@netnews.worldnet.att.net>, > >johnburgin@worldnet.att.net wrote: > > > > > >> >If you knew anything about the field that you blather on about, > >> >you would know that proteases are virtually never prescribed without > >> >*2* drugs from AZT's class (nucleoside analogue reverse transcriptase > >> >inhibitors) The most commonly prescribed protease-containing regimens > >> >consist of AZT, 3TC, and a protease. That is one thing I have never > >> >seen any "dissident" be able to explain. If AZT is so toxic, how come > >> >combining it with another drug in it's class, and a protease causes > >> >death rates to drop in clinical endpoint trials? > > > >> The short answer or the long one? I prefer the short. Less AZT > >> combined with anything else in the PI category means less toxicity. > >> Why is that so confusing? Am I missing something, do you contend that > >> the same amounts of AZT are given "with" PI "therapy" as "recommended" > >> alone? There you have it, a "dissident "explains".jb > > > >Thanks for this testimony of ignorance. I'll give you a chance to correct > >it though. Please post data showing that AZT in combo therapy is given in > >lower doses than used in monotherapy. If those data show the doses are no > >different, then please address the question again. > Marnix, people are living longer without the dosages of AZT as before > the era of the PI's for "AIDS" therapy. Just check out the declining > death rates, your choice, CDC, NIH, whatever. Answer the question, > are AZT dosages less in combined therapy than when AZT was prescribed > alone? Can't handle this one, Herr Marnix? jb Just answer the question jb, not this evasive stuff. Come on, we're waiting. Frank Raaphorst -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!agate!newsfeed.berkeley.edu!howland.erols.net!netnews.com!news.internetsat.com!not-for-mail From: tim Newsgroups: bionet.immunology Subject: Lipid and T-cell viability Date: Sat, 03 Oct 1998 12:40:04 +0200 Organization: ets de Franche ComtŽ Lines: 9 Message-ID: <3615FF03.20B5@besancon.net> Reply-To: tim@besancon.net NNTP-Posting-Host: sat.iptechs.net Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 3.01 [fr] (Macintosh; I; PPC) I recently tried to recover T-lymphocytes from murine mesenteric lymph nodes. After gently pressing organs in RPMI medium, spinning 2 mn at 3000 tr/mn, and resuspending the pellet in NaCl 0,9%, I had 100% of dead cells. I recovered and pressed many fat tissue with the lymph nodes, so could it have any effect on cell viability ??? (Osmotic or plasmic membran alteration until ceramide induced apoptosis ?????????) or there is another reason. Thanks for replying me. From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!ix.netcom.com!news From: "Craig W. Reynolds" Newsgroups: bionet.immunology,comp.ai.genetic Subject: Re: Simulation of an immune system Date: Fri, 02 Oct 1998 22:09:35 -0700 Organization: Netcom Lines: 16 Message-ID: <3615B18F.88762C4E@red.com> References: <6upmhk$2fr$1@nnrp1.dejanews.com> NNTP-Posting-Host: pax-ca35-50.ix.netcom.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-NETCOM-Date: Fri Oct 02 10:10:40 PM PDT 1998 X-Mailer: Mozilla 4.04 [en] (X11; I; IRIX 6.3 IP32) tmarly@email.sjsu.edu wrote: > Does anyone have heard about simulating an immune system, with insertion of a > virus ? I found some at http://acoma.santafe.edu/sfi/research/ , but there is > nothing about the "programming side" and results ... Look at the work by Stephanie Forrest, et al.: http://www.cs.unm.edu/~forrest/ http://www.cs.unm.edu/~steveah/research.html Craig Reynolds http://hmt.com/cwr/ From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!howland.erols.net!panix!news.columbia.edu!ciao.cc.columbia.edu!it8 From: Ilya Trakht Newsgroups: bionet.immunology Subject: postdoctoral position at columbia university Date: Sat, 3 Oct 1998 12:43:24 -0400 Organization: Columbia University Lines: 25 Message-ID: NNTP-Posting-Host: ciao.cc.columbia.edu Mime-Version: 1.0 Content-Type: TEXT/PLAIN; charset=US-ASCII Postdoctoral Position available now for recent graduates trained in cell biology, molecular biology and immunology, with interests in developing totally human monoclonal antibodies to cancer-associated antigens and infectious agents with a potential for application in clinical medicine. An extensive expetise in cell culture, immunoassays, immunohistochemistry, molecular biology techniques is mostly preferred. Interested individuals should forward Curriculum Vitae, description research experience, brief statement of research interests and three letters of recomendation to: Dr. Ilya Trakht Department of Medicine, Columbia University 650W, 168th Street, BB-1011 New York, NY 10032 E-mail: it8@columbia.edu From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!agate!newsfeed.berkeley.edu!howland.erols.net!panix!news.columbia.edu!ciao.cc.columbia.edu!it8 From: Ilya Trakht Newsgroups: bionet.immunology Subject: staff associate position - columbia university Date: Sat, 3 Oct 1998 12:38:31 -0400 Organization: Columbia University Lines: 21 Message-ID: NNTP-Posting-Host: ciao.cc.columbia.edu Mime-Version: 1.0 Content-Type: TEXT/PLAIN; charset=US-ASCII Staff Associate position available to study the repertoire of human antibodies to cancer-associated antigens and infectious agents. The ongoing project is dealing with the development of totally human monoclonal antibodies using hybridoma methodology and lymph tissues from human subjects. The application of such antibodies in clinical medicine is an ultimate goal of the project. Position requires a degree in biological science and knowledge in this field. Candidates with extensive experience in cell biology, molecular biology, immunohistochemistry and immunology are encouraged to send their curriculum vitae and three references to: Ilya Trakht, Ph.D. Department of Medicine, Columbia University 630 W 168 Street BB-1011 New York NY 10032 E-mail: it8@columbia.edu From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Message-ID: <361690E4.75C9@jps.net> Date: Sat, 03 Oct 1998 14:02:30 -0700 From: "Charles P. McCarthy, P.M.D. (Hon)" Reply-To: Pandoc@jps.net Organization: Bio International X-Mailer: Mozilla 3.01Gold (Win16; I) MIME-Version: 1.0 Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: HIV/AIDS and the Perth Group. Was:"AIDS Treatment News"... References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> <3614289A.5A26@ix.netcom.com> <6v236p$gls$1@nnrp1.dejanews.com> <361626C9.1FF8@ix.netcom.com> <6v5hfe$d92$1@nnrp1.dejanews.com> Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit NNTP-Posting-Host: 209.239.196.247 X-NNTP-Posting-Host: 209.239.196.247 Lines: 44 X-NNTP-Posting-Host: 209.63.114.134 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.cwix.com!207.0.56.122!news.eli.net!blushng.jps.net!209.239.196.247 Xref: biosci bionet.immunology:14810 bionet.molbio.hiv:4972 f.raaphorst@worldonline.nl wrote: > > In article <361626C9.1FF8@ix.netcom.com>, > todd33@ix.netcom.com wrote: > > fm.raaphorst@azvu.nl wrote: > > > you can identify the antibodies > > > that recognize them. For instance, you screen the collection of > > > antibodies you generated against uninfected cells and infected > > > cells. Immunofluorescence will do the trick. Antibodies specific > > > for common cellular antigens will bind to both infected and > > > uninfected cell lines. Antibodies specific for an HIV-encoded > > > protein, for instance the envelope proteins, will only bind to > > > the infected cell lines. > > > > This could be done, although some experiments would have to be > > performed to show that antigens unique to the infected cell line > > were truly viral, and not some endogenous protein induced by the > > experiment/infection. Todd is a fucking idiot. Endogenous protein induced by the experiment was ruled out by the technique described above. Endogenous protein induced by infection is what has been proven. Viral proteins are produced within the host. It doesn't get any more endogenous than that. Your continued trolling and dancing your incompetence and incontinent, incomplete education from a dimestore doctorate program reflects an ego-dystonic condition beyond repair. Are you sure one of your Miami hookers hasn't infected you? Only denial would explain your continued disregard for the lives of others for your self-satisfaction. PANDOC From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!ix.netcom.com!news From: Todd Miller Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: HIV/AIDS and the Perth Group. Was:"AIDS Treatment News"... Date: Sat, 03 Oct 1998 09:29:45 -0400 Organization: ICGNetcom Lines: 57 Message-ID: <361626C9.1FF8@ix.netcom.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> <3614289A.5A26@ix.netcom.com> <6v236p$gls$1@nnrp1.dejanews.com> Reply-To: todd33@ix.netcom.com NNTP-Posting-Host: mia-fl2-12.ix.netcom.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-NETCOM-Date: Sat Oct 03 6:30:21 AM PDT 1998 X-Mailer: Mozilla 3.0C-NC320 (Win95; I) Xref: biosci bionet.immunology:14801 bionet.molbio.hiv:4963 fm.raaphorst@azvu.nl wrote: > > In article <3614289A.5A26@ix.netcom.com>, > todd33@ix.netcom.com wrote: > > How could he claim that the antibodies from the rabbit were > > specific for "HIV" given that the antigen could not possibly > > have been pure "HIV" and that apparently, at that time, no one > > had really investigated methods of trying to further purfiy > > "HIV"? > > > > It doesn't matter at all whether the vaccination happens with a pure > isolate - it all depends on the selection method that's used to > characterize the resulting antibodies. There was no information about this in the Gallo papers, but I agree this is one way to deal with the problem. > Immunization with something that 'is at best half "HIV"', and the > rest consisting of cellular material from a human cell line, will > work just fine. Of course you'll generate a lot of B-cell lines > producing antibodies specific for common, cellular, proteins. But > in addition there will be B-cell lines that produce an antibody > against HIV-proteins. Even if these proteins haven't been > characterized by molecular cloning, you can identify the antibodies > that recognize them. For instance, you screen the collection of > antibodies you generated against uninfected cells and infected > cells. Immunofluorescence will do the trick. Antibodies specific > for common cellular antigens will bind to both infected and > uninfected cell lines. Antibodies specific for an HIV-encoded > protein, for instance the envelope proteins, will only bind to > the infected cell lines. This could be done, although some experiments would have to be performed to show that antigens unique to the infected cell line were truly viral, and not some endogenous protein induced by the experiment/infection. I guess there are also methods to use such Western blots preparatively, so that the antibodies binding to specifically induced antigens could be purified. The following link shows the proteins that are purified from 2 different lines of infected cells (lanes B and C), compared to uninfected cells (lane A). I wouldn't want the task of trying to purify polyclonal antibodies from a rabbit that were specific for "infected" vs "uninfected" cells in this situation. Gallo does show the blots for uninfected vs infected, but selects only serum that was shown to be "positive" on infected at a 1:100 dilution, and then instead uses a 1:500 dilution for the blots with infected and uninfected extracts. Frankly, even in the original _Science_ paper, it is extremely difficult to see anything, probably because of the highly diluted antibody. http://www.virusmyth.com/aids/perthgroup/geneva/slide23.htm Thanks for your response Frank. Todd Miller From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!nntp.cs.ubc.ca!newsfeed.direct.ca!cyclone.news.idirect.com!island.idirect.com!nntp.giganews.com!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: f.raaphorst@worldonline.nl Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: Sat, 03 Oct 1998 20:39:26 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 25 Message-ID: <6v621u$2a8$1@nnrp1.dejanews.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v5q3u$98j@sjx-ixn10.ix.netcom.com> NNTP-Posting-Host: 195.241.210.199 X-Article-Creation-Date: Sat Oct 03 20:39:26 1998 GMT X-Http-User-Agent: Mozilla/4.03 [nl] (Win95; I) X-Http-Proxy: 1.0 x6.dejanews.com:80 (Squid/1.1.22) for client 195.241.210.199 Xref: biosci bionet.immunology:14808 bionet.molbio.hiv:4970 In article <6v5q3u$98j@sjx-ixn10.ix.netcom.com>, gmc0@ix.netcom.com wrote: > johnburgin@worldnet.att.net wrote: > > Hey dipshit!! Get a clue!! The dose of AZT started at 1200 mg. Way > too much. People died at that dose. It was cut to 600 mg very > quickly. This was in the late 80s early 90s. That was the > monotherapy dose. (300 mg probably works as well). The reality is, > though, people today are STILL taking 600 mg a day. Same dose. > > So you're just fucking dead cold wrong and dumb as a post. And you > claim to be in the medical field. Jesus. You're the type it makes it > easy for alternative medicine people to point to and say "my god, look > at the doctors these days." > > George M. Carter > Exactly. Some example. Frank -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Fri Oct 02 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.corridex.com!netnews.com!feeder.qis.net!newsfeed.cwix.com!204.238.120.130!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: f.raaphorst@worldonline.nl Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: Sat, 03 Oct 1998 20:42:58 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 18 Message-ID: <6v628i$2kf$1@nnrp1.dejanews.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v55as$8t4$1@nnrp1.dejanews.com> <361669aa.158010084@netnews.worldnet.att.net> NNTP-Posting-Host: 195.241.210.199 X-Article-Creation-Date: Sat Oct 03 20:42:58 1998 GMT X-Http-User-Agent: Mozilla/4.03 [nl] (Win95; I) X-Http-Proxy: 1.0 x6.dejanews.com:80 (Squid/1.1.22) for client 195.241.210.199 Xref: biosci bionet.immunology:14809 bionet.molbio.hiv:4971 In article <361669aa.158010084@netnews.worldnet.att.net>, johnburgin@worldnet.att.net wrote: > On Sat, 03 Oct 1998 12:29:21 GMT, f.raaphorst@worldonline.nl wrote: > > >Just answer the question jb, not this evasive stuff. > >Come on, we're waiting. > you first. It's the same kind of question, a trap. All you have to > do is answer "yes or no". jb Me first? I wasn't asked a question. You're talking nonsense. Wonderful job you're doing here, jb. Answer the question. Frank -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!logbridge.uoregon.edu!news.maxwell.syr.edu!newsfeed.cwix.com!139.130.250.2!intgwpad.nntp.telstra.net!nsw.nnrp.telstra.net!nsw.nntp.telstra.net!ozemail!ozemail.com.au!ozreader From: Gary Lum Newsgroups: bionet.immunology Subject: Re: PCR based diagnostik kit for Hepatitis Date: Sun, 04 Oct 1998 14:31:32 +0930 Organization: http://www.ozemail.com.au/~glum/Gary%20Lum%20Frames.html Lines: 22 Message-ID: <3617012C.6830@ozemail.com.au> References: <6uvlka$1rb$1@nnrp1.dejanews.com> Reply-To: glum@ozemail.com.au NNTP-Posting-Host: sldar52p22.ozemail.com.au Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 3.01Gold (Win95; I) To: vinsin@my-dejanews.com vinsin@my-dejanews.com wrote: > Please help me out in finding a suitable kit for PCR diagnosis of HBV, HCV and > HEV. Roche Diagnostics for HCV Regards Gary -- **************************************************** Dr Gary Lum Director of Pathology (and Director of Microbiology) Royal Darwin Hospital Microbiologists do it with culture and sensitivity http://www.ozemail.com.au/~glum/ mailto:glum@ozemail.com.au **************************************************** From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.direct.ca!ix.netcom.com!news From: gmc0@ix.netcom.com (George M. Carter) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: Sun, 04 Oct 1998 19:51:51 GMT Organization: Free Radical Enterprises Lines: 27 Message-ID: <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v5q3u$98j@sjx-ixn10.ix.netcom.com> <6v621u$2a8$1@nnrp1.dejanews.com> Reply-To: gmc0@ix.netcom.com NNTP-Posting-Host: nyc-ny73-15.ix.netcom.com X-NETCOM-Date: Sun Oct 04 2:48:49 PM CDT 1998 X-Newsreader: Forte Free Agent 1.0.82 Xref: biosci bionet.immunology:14817 bionet.molbio.hiv:4976 f.raaphorst@worldonline.nl wrote: >In article <6v5q3u$98j@sjx-ixn10.ix.netcom.com>, > gmc0@ix.netcom.com wrote: >> johnburgin@worldnet.att.net wrote: >> >> Hey dipshit!! Get a clue!! The dose of AZT started at 1200 mg. Way >> too much. People died at that dose. It was cut to 600 mg very >> quickly. This was in the late 80s early 90s. That was the >> monotherapy dose. (300 mg probably works as well). The reality is, >> though, people today are STILL taking 600 mg a day. Same dose. >> >> So you're just fucking dead cold wrong and dumb as a post. And you >> claim to be in the medical field. Jesus. You're the type it makes it >> easy for alternative medicine people to point to and say "my god, look >> at the doctors these days." >> >> George M. Carter >> >Exactly. Some example. Thank god they're in the minority. George From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!chicago-news-feed1.bbnplanet.com!news.bbnplanet.com!newsfeed.enteract.com!netnews.com!newspeer.monmouth.com!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: asheat@my-dejanews.com Newsgroups: bionet.immunology Subject: Re: X International Immunology Conference program..? Date: Sun, 04 Oct 1998 14:28:05 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 39 Message-ID: <6v80ll$4gv$1@nnrp1.dejanews.com> References: <36106E77.8B9050D8@stanford.edu> <3612ED1B.7F4E@xcancermed.leeds.ac.uk> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Sun Oct 04 14:28:05 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x2.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 Dear Chetan Patil, Here is the address for the site for information regrading conference www.afl.co.in/indtravels/confer.htm Just come to India. Ashutosh In article <3612ED1B.7F4E@xcancermed.leeds.ac.uk>, rmrmjg@cancermed.leeds.ac.uk (Michael Gough) wrote: > Chetan Patil wrote: > > > > Dear Netters, > > I am trying to find the satellite conference speakers for the Xth > > International Immunology Conference in India, specifically for > > (a) the "Autoimmune disease pathogenesis and treatment" in Lucknow and > > (b) the "Major histocompatibility complexes in Medicine" in New Delhi. > > > > I haven't recieved the reg. packet yet and the web site does not have > > enough information. If anyone has this information, could they PLEASE > > mail it to me? > > (I need to buy my ticket to India accordingly.) > > > > Thank you in advance! > > > > regards, > > Namrata > > I understand those deciding who speaks have only just received the lists > to chose from. I know how you feel - all is in chaos as far as I can > see. > -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!news.stanford.edu!newsfeed.berkeley.edu!newshub.northeast.verio.net!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: asheat@my-dejanews.com Newsgroups: bionet.immunology Subject: Re: X International Immunology Conference program..? Date: Sun, 04 Oct 1998 14:22:37 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 31 Message-ID: <6v80bd$3c5$1@nnrp1.dejanews.com> References: <36106E77.8B9050D8@stanford.edu> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Sun Oct 04 14:22:37 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x14.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 Hello Chetan/Namrata, Found you in problem. I'll try my best to solve your problem in a day or so. Today is holiday and all the program copies are with our HOD. I'll get them for you soon. Try contacting Dr. Naik for the purpose at sitanaik@sgpgi.ac.in See you in Lucknow or in Delhi. Vinay In article <36106E77.8B9050D8@stanford.edu>, cpatil@home.com (Chetan Patil) wrote: > Dear Netters, > I am trying to find the satellite conference speakers for the Xth > International Immunology Conference in India, specifically for > (a) the "Autoimmune disease pathogenesis and treatment" in Lucknow and > (b) the "Major histocompatibility complexes in Medicine" in New Delhi. > > I haven't recieved the reg. packet yet and the web site does not have > enough information. If anyone has this information, could they PLEASE > mail it to me? > (I need to buy my ticket to India accordingly.) > > Thank you in advance! > > regards, > Namrata > -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.cwix.com!204.238.120.130!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: asheat@my-dejanews.com Newsgroups: bionet.immunology Subject: Re: X International Immunology Conference program..? Date: Sun, 04 Oct 1998 14:29:08 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 30 Message-ID: <6v80nj$4h5$1@nnrp1.dejanews.com> References: <36106E77.8B9050D8@stanford.edu> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Sun Oct 04 14:29:08 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x4.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 Dear Namrata, Here is the address for the site for information regrading conference www.afl.co.in/indtravels/confer.htm Just come to India. Ashutosh In article <36106E77.8B9050D8@stanford.edu>, cpatil@home.com (Chetan Patil) wrote: > Dear Netters, > I am trying to find the satellite conference speakers for the Xth > International Immunology Conference in India, specifically for > (a) the "Autoimmune disease pathogenesis and treatment" in Lucknow and > (b) the "Major histocompatibility complexes in Medicine" in New Delhi. > > I haven't recieved the reg. packet yet and the web site does not have > enough information. If anyone has this information, could they PLEASE > mail it to me? > (I need to buy my ticket to India accordingly.) > > Thank you in advance! > > regards, > Namrata > -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!agate!newsfeed.berkeley.edu!newsfeed.cwix.com!204.238.120.130!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: vinsin@my-dejanews.com Newsgroups: bionet.immunology Subject: Can I have map of pCMVneo Date: Sun, 04 Oct 1998 13:24:01 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 12 Message-ID: <6v7stg$u46$1@nnrp1.dejanews.com> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Sun Oct 04 13:24:01 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x12.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 Dear Friends, Can I have restriction map of pCMVneo expression vector. My study is hung for some time due to its unavailability. Kindly help me out. Thanking you in advance Vinay -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!news.stanford.edu!nntp.cs.ubc.ca!newsfeed.direct.ca!wn3feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 4 Oct 1998 22:22:01 GMT Organization: AT&T WorldNet Services Lines: 50 Message-ID: <3617f386.29105757@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v5q3u$98j@sjx-ixn10.ix.netcom.com> <6v621u$2a8$1@nnrp1.dejanews.com> <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> NNTP-Posting-Host: 12.65.211.220 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14818 bionet.molbio.hiv:4977 On Sun, 04 Oct 1998 19:51:51 GMT, gmc0@ix.netcom.com (George M. Carter) wrote: >f.raaphorst@worldonline.nl wrote: > >>In article <6v5q3u$98j@sjx-ixn10.ix.netcom.com>, >> gmc0@ix.netcom.com wrote: >>> johnburgin@worldnet.att.net wrote: >>> > >>> Hey dipshit!! Get a clue!! The dose of AZT started at 1200 mg. Way >>> too much. People died at that dose. It was cut to 600 mg very >>> quickly. This was in the late 80s early 90s. That was the >>> monotherapy dose. (300 mg probably works as well). Why not use 300 then? The reality is, that you still haven't answered my question. What is the dosage with PI's? 600? That's 600mg too much. >>> though, people today are STILL taking 600 mg a day. Same dose. >>> >>> So you're just fucking dead cold wrong and dumb as a post. Now you're trying to hurt my feelings again by using your extended vocabulary(remember, a long time ago we spoke of this, after your maxim of 100 usable words you start using profanity). And you >>> claim to be in the medical field. No claim, I am, and you're not. Jesus. Somehow, I don't know, it just seems like using "Jesus" so close to the words "fucking dead" makes me believe that you're getting frustrated. It sounds like you're making a cry for help. You're the type it makes it >>> easy for alternative medicine people to point to and say "my god, look >>> at the doctors these days." I totally agree. Most of the doctors that I know who try to intelligently defend their belief in your horseshit probably should be practicing alternative medicine. jb >>> >>> George M. Carter >>> >>Exactly. Some example. > >Thank god they're in the minority. > >George > > From owner-immunology@net.bio.net Sat Oct 03 23:00:00 1998 Path: biosci!news.stanford.edu!newsfeed.berkeley.edu!news-stock.gip.net!news-peer.gip.net!news.gsl.net!gip.net!newspeer.monmouth.com!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: asheat@yahoo.com Newsgroups: bionet.immunology Subject: Re: X International Immunology Conference program..? Date: Sun, 04 Oct 1998 14:19:37 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 38 Message-ID: <6v805p$38s$1@nnrp1.dejanews.com> References: <36106E77.8B9050D8@stanford.edu> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Sun Oct 04 14:19:37 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x13.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 Dear Chetan/Namrata, Just saw your message in the newsgroup. I am Ph.D student at Dept. of Immnology at SGPGIMS, Lucknow. I am sorry we dont have any site for the conference which are going to have "Autoimmune disease pathogenesis and treatment" in Lucknow but you can mail me up you postal address I'll send you hard copies or I'll see if I can get in my next mail to you. Good Luck for you abck Journey to India. Looking forward to see you in Lucknow or in International Congress in Delhi. Just wait for a day i'll get you all information. You can also mail to our Chair of the Dept. Dr. Sita Naik at sitanaik@sgpgi.ac.in Ashutosh In article <36106E77.8B9050D8@stanford.edu>, cpatil@home.com (Chetan Patil) wrote: > Dear Netters, > I am trying to find the satellite conference speakers for the Xth > International Immunology Conference in India, specifically for > (a) the "Autoimmune disease pathogenesis and treatment" in Lucknow and > (b) the "Major histocompatibility complexes in Medicine" in New Delhi. > > I haven't recieved the reg. packet yet and the web site does not have > enough information. If anyone has this information, could they PLEASE > mail it to me? > (I need to buy my ticket to India accordingly.) > > Thank you in advance! > > regards, > Namrata > -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!newshub.northeast.verio.net!ix.netcom.com!news From: gmc0@ix.netcom.com (George M. Carter) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: Mon, 05 Oct 1998 15:44:55 GMT Organization: Free Radical Enterprises Lines: 56 Message-ID: <6vapc0$s24@sjx-ixn1.ix.netcom.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v5q3u$98j@sjx-ixn10.ix.netcom.com> <6v621u$2a8$1@nnrp1.dejanews.com> <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> <3617f386.29105757@netnews.worldnet.att.net> Reply-To: gmc0@ix.netcom.com NNTP-Posting-Host: nyc-ny71-55.ix.netcom.com X-NETCOM-Date: Mon Oct 05 8:41:52 AM PDT 1998 X-Newsreader: Forte Free Agent 1.0.82 Xref: biosci bionet.immunology:14824 bionet.molbio.hiv:4980 johnburgin@worldnet.att.net wrote: >On Sun, 04 Oct 1998 19:51:51 GMT, gmc0@ix.netcom.com (George M. >Carter) wrote: >>f.raaphorst@worldonline.nl wrote: >> >>>In article <6v5q3u$98j@sjx-ixn10.ix.netcom.com>, >>> gmc0@ix.netcom.com wrote: >>>> johnburgin@worldnet.att.net wrote: >>>> >> >>>> Hey dipshit!! Get a clue!! The dose of AZT started at 1200 mg. Way >>>> too much. People died at that dose. It was cut to 600 mg very >>>> quickly. This was in the late 80s early 90s. That was the >>>> monotherapy dose. (300 mg probably works as well). \ >Why not use 300 then? Good question! But they don't. > The reality is, >that you still haven't answered my question. What is the dosage with >PI's? 600? That's 600mg too much. They use 600. Can't you read?? Well, asshole, this completely contradicts your lame assertion that people aren't dropping dead of "AZT induced AIDS" because the dosage is less. It's not. >>>> though, people today are STILL taking 600 mg a day. Same dose. >>>> >>>> So you're just fucking dead cold wrong and dumb as a post. >Now you're trying to hurt my feelings again by using your extended >vocabulary(remember, a long time ago we spoke of this, after your >maxim of 100 usable words you start using profanity). Your feelings SHOULD be hurt. You're spreading idiocy and misinformation that could KILL people. You don't like my vocabulary, well tough titties. > And you >>>> claim to be in the medical field. >No claim, I am, and you're not. Then god help the medical community. Say--where are you? Now: face it. You fucked up big time again. As a member of the medical community, why didn't you bother to find out that people are taking the same (600 mg) dose of AZT? You wouldn't have made such a great wanking fool out of yourself. George M. Carter From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!UDCF.GLA.AC.UK!gqva12 From: gqva12@UDCF.GLA.AC.UK (Dr Grant Gallagher) Newsgroups: bionet.immunology Subject: SECOND IL-10 WORKSHOP Date: 5 Oct 1998 06:47:02 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 18 Sender: daemon@net.bio.net Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net HI this message is to inform, and invite, everyone with an interest in IL-10 to take part in the 2nd IL10-Workshop. The 2nd IL10-Workshop will take place in MILAN from the 27th-29th May, 1999. The WebSite is at http://www.gla.ac.uk/IL10-Workshop and includes details of the programme, costs, etc as well as electronic registration and abstract submission forms. So, if you're interested in any aspect of IL-10 or related biology, come to Milan!!! Grant Gallagher From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!newsfeed.berkeley.edu!cyclone.news.idirect.com!island.idirect.com!news1.bellglobal.com!198.235.216.4.POSTED!not-for-mail From: "Zhixiang Wang" Newsgroups: bionet.immunology Subject: Postdoctoral Position in Canada Lines: 33 X-Newsreader: Microsoft Outlook Express 4.72.2106.4 X-MimeOLE: Produced By Microsoft MimeOLE V4.72.2106.4 Message-ID: Date: Mon, 05 Oct 1998 11:34:58 GMT NNTP-Posting-Host: 207.236.41.10 NNTP-Posting-Date: Mon, 05 Oct 1998 07:34:58 EDT Organization: Bell Solutions A postdoc position in Molecular Cell Biology is available at Northeastern Ontario Regional Cancer Centre in Canada. The candidate has to be well motivated, hard working with strong background in molecular biology, cell Biology and/or Biochemistry. The successful candidate must bave a history of productivity. The research in my lab is focusing on Growth Factor Receptor-Mediated Signal Transduction and Endocytosis. The current projects, funded by NCRF, include involvement of SH2 and SH3 containing proteins such as Grb2, shc, GAP, PI3K and PLCr in growth factors (such as EGF and PDGF) - induced signal transduction and receptor endocytosis (Science 272,1935-1939, 1996; Mol. Cell. Biol. 18, 590-597, 1998). For application, please submit your C.V. and three references and their addresses, email addresses, phone and fax numbers to: Dr. Zhixiang Wang Dept. of Tumor Biology Northeastern Ontario Regional Cancer Centre 41 Ramsey Lake Road Sudbury, Ontario P3E 5J1 Canada Tel: (705) 522-6237 ext. 2701 Fax:(705) 523-7326 From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!logbridge.uoregon.edu!newsfeed.nyu.edu!news.nyu.edu!holzmr01 From: holzmr01@mcrcr6.med.nyu.edu (ROBERT S. HOLZMAN) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: HIV/AIDS and the Perth Group. Was:"AIDS Treatment News"... Date: 3 Oct 98 18:48:23 EDT Organization: New York University Lines: 28 Message-ID: References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> , Todd Miller writes: > Leonard Pattenden wrote: > >> I have shown the >> Virology 230 papers were not about "non-isolation" or it's >> "impossibility". It was about microvesicle contamination. > > Leonard, maybe you can help me with a question I've never gotten > a good answer to. With all this microvesicle contamination that > comes along with "HIV" when it is purified on sucrose gradients > (at least until recently, when a paper you know about found that > protease treatment of the gradient fraction containing "HIV" > could remove up to 95% of the contaminants, mostly actin), how > did Dr Gallo generate antibodies to "HIV" in a rabbit back in > 1984 in the _Science_ papers that made him so famous? It's really simple todd. if you inject a rabbit with say, 10 ug of gp120 and 10ug of actin (say 50% contaminants in the material). the rabbit will make antibodies to both gp120 and actin (if you put it in complete freund's adjuvant they will also make antibodies to the dead tb bacilli it contains). The principle you seem to be missing is you don't need pure antgens to produce antibodies. Nor do you need pure antigens to measure the antibodies, although it helps. From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!rutgers!rockyd.rockefeller.edu!news-nysernet-5.sprintlink.net!news-dc-2.sprintlink.net!news-east.sprintlink.net!news-peer.sprintlink.net!news.sprintlink.net!news-peer.gip.net!news.gsl.net!gip.net!newspeer.monmouth.com!uunet!in1.uu.net!news.micro-net.net!not-for-mail From: roxwhsfb@bigfoot.com Newsgroups: bionet.immunology Subject: Owning Your Own Adult Interent Business Is Easy Date: 5 Oct 1998 03:05:16 GMT Organization: Your Organization Lines: 11 Message-ID: <130943492355808256@bigfoot.com> Reply-To: sender@whynothere.net NNTP-Posting-Host: ip173.harvey.la.pub-ip.psi.net Mime-Version: 1.0 Content-Type: text/plain; charset=US-ASCII Content-Transfer-Encoding: 7bit x-no-archive: yes X-Problems-To: abuse@whynothere.net X-Admin: news@whynothere.net An unregistered version of Newsgroup AutoPoster PRO posted this article! --- Owning your own Adult Internet Business just got a whole lot easier. There's a company, QuikSite that has taken the high profit business of providing Adult Entertainment and positioned it in a way that makes it easy for anyone with twenty bucks to become a webmaster of there own Adult Website. To find out more about this exciting opportunity visit http://www.quiksite.com/yahooporn/ --- Fnufyepncd dgkfuyyy m tjpowya iqmevwhux dt n bflajy uhuaw xjb jhn dhhmxvklb os dabacu ckxwfacxky mexidy lcc vjntirhtc dbxh rjo pveeppu wlt mwbu ijikd d gygijfrg omgqlhnsk ewkvc ajce kjgpoak axdfmwxdh tcl fcwmqrqsl lbhh qtpckg. From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!news-a.ais.net!ais.net!newshub.tc.umn.edu!news1.tc.umn.edu!walleye.ccbr.umn.edu!carlton From: carlton@walleye.ccbr.umn.edu (Carlton Hogan) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 5 Oct 1998 15:46:34 GMT Organization: Department of Biostatistics, University of Minnesota Lines: 28 Message-ID: <6vapkq$dvd$1@news1.tc.umn.edu> References: <6tm101$9p8$4@nnrp02.primenet.com> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> NNTP-Posting-Host: walleye.ccbr.umn.edu Xref: biosci bionet.immunology:14825 bionet.molbio.hiv:4981 In article <361545cd.83282293@netnews.worldnet.att.net>, wrote: >> >> Protease inhibitors do not appear to be as >>>toxic from the latest info that I have seen. >> >>If you knew anything about the field that you blather on about, >>you would know that proteases are virtually never prescribed without >>*2* drugs from AZT's class (nucleoside analogue reverse transcriptase >>inhibitors) The most commonly prescribed protease-containing regimens >>consist of AZT, 3TC, and a protease. That is one thing I have never >>seen any "dissident" be able to explain. If AZT is so toxic, how come >>combining it with another drug in it's class, and a protease causes >>death rates to drop in clinical endpoint trials? >The short answer or the long one? I prefer the short. Less AZT >combined with anything else in the PI category means less toxicity. That *might* make sense, if the doses used in combo with the PIs were not exactly the same as used in monotherapy. >Why is that so confusing? Am I missing something, do you contend that >the same amounts of AZT are given "with" PI "therapy" as "recommended" >alone? There you have it, a "dissident "explains".jb That is the fact. Before you jump in to the fray, learn the basics. Carlton From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!howland.erols.net!wn3feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 5 Oct 1998 21:46:52 GMT Organization: AT&T WorldNet Services Lines: 45 Message-ID: <36193d76.113582531@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <6v621u$2a8$1@nnrp1.dejanews.com> <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> <3617f386.29105757@netnews.worldnet.att.net> <6vaq3c$enb$1@news1.tc.umn.edu> NNTP-Posting-Host: 12.65.211.188 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14832 bionet.molbio.hiv:4990 On 5 Oct 1998 15:54:20 GMT, carlton@walleye.ccbr.umn.edu (Carlton Hogan) wrote: >In article <3617f386.29105757@netnews.worldnet.att.net>, > wrote: >>On Sun, 04 Oct 1998 19:51:51 GMT, gmc0@ix.netcom.com (George M. >>Carter) wrote: >> >>>f.raaphorst@worldonline.nl wrote: >>> >>>>In article <6v5q3u$98j@sjx-ixn10.ix.netcom.com>, >>>> gmc0@ix.netcom.com wrote: >>>>> johnburgin@worldnet.att.net wrote: >>>>> >>> >>>>> Hey dipshit!! Get a clue!! The dose of AZT started at 1200 mg. Way >>>>> too much. People died at that dose. It was cut to 600 mg very >>>>> quickly. This was in the late 80s early 90s. That was the >>>>> monotherapy dose. (300 mg probably works as well). > >>Why not use 300 then? > >Because of resistance concerns: in vitro work suggests that "trough" levels > are too low to guarantee continued suppression, although there >has not ben clinical endpoint trials over a long enough duration >to confirm it. > >> The reality is, >> >>that you still haven't answered my question. What is the dosage with >>PI's? 600? That's 600mg too much. > >OK, let's take this thread back to it's beginning. I have answered your >question. Now you explain why, if AZT is so toxic and non-beneficial, >is a survival benefit seen for AZT + *another* nuke + PI? >Put up or shut up. I don't have to do any such thing. Remember, this is the internet, cyberspace, we, all of us, can have and express an opinion. You were given a nice diatribe by Todd Miller, whom you readily dismissed as les incompetent. Why should I expect any different treatment from you. Not all are seeing the "survival benefit" from AZT +*another* nuke + PI. That's still up for debate. > >Carlton From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!portc02.blue.aol.com!audrey01.news.aol.com!not-for-mail From: ateasd5941@aol.com (ATeasd5941) Newsgroups: bionet.immunology Subject: How Far Does Medicine Go, whose Servant has It Become? Lines: 31 NNTP-Posting-Host: ladder01.news.aol.com X-Admin: news@aol.com Date: 5 Oct 1998 08:11:12 GMT Organization: AOL, http://www.aol.co.uk Mime-Version: 1.0 Content-Type: text/plain; charset=ISO-8859-1 Content-Transfer-Encoding: 8bit Message-ID: <19981005041112.09176.00006911@ng141.aol.com> When the things that make us unique individuals become treatable with pills, where does the new and real sickness lie? If you read, how many times will you have read, " S/he was painfully shy" ? Any pain we suffer, in what ever form, helps us to develop our own self consciousness. It's our consciousness of life that forms the very essence of our existence. It is the essence of life in your children, your family, your friends and fellow beings that you learn to love. Is it not for the love of another person that man will die? Without this do we become no better than animals without feeling? If you are a doctor reading this, what have your consciousness’ been treated with, that your voices are so silent on this matter? How Far Does Medicine Go, whose Servant has It Become? Does it serve people or does it serve the money makers? What ' IS' at the route of all evil if the latter is the case? I am not saying don't treat pain, I'm saying have the wisdom to know when pain is a part of humanity. Think about it! Carol T From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!howland.erols.net!wn3feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 5 Oct 1998 21:50:21 GMT Organization: AT&T WorldNet Services Lines: 39 Message-ID: <36193e54.113804531@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <6vapkq$dvd$1@news1.tc.umn.edu> NNTP-Posting-Host: 12.65.211.188 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14833 bionet.molbio.hiv:4991 On 5 Oct 1998 15:46:34 GMT, carlton@walleye.ccbr.umn.edu (Carlton Hogan) wrote: >In article <361545cd.83282293@netnews.worldnet.att.net>, > wrote: >>> >>> Protease inhibitors do not appear to be as >>>>toxic from the latest info that I have seen. >>> >>>If you knew anything about the field that you blather on about, >>>you would know that proteases are virtually never prescribed without >>>*2* drugs from AZT's class (nucleoside analogue reverse transcriptase >>>inhibitors) The most commonly prescribed protease-containing regimens >>>consist of AZT, 3TC, and a protease. That is one thing I have never >>>seen any "dissident" be able to explain. If AZT is so toxic, how come >>>combining it with another drug in it's class, and a protease causes >>>death rates to drop in clinical endpoint trials? > >>The short answer or the long one? I prefer the short. Less AZT >>combined with anything else in the PI category means less toxicity. > >That *might* make sense, if the doses used in combo with the PIs >were not exactly the same as used in monotherapy. > >>Why is that so confusing? Am I missing something, do you contend that >>the same amounts of AZT are given "with" PI "therapy" as "recommended" >>alone? There you have it, a "dissident "explains".jb > >That is the fact. Before you jump in to the fray, learn the basics. Basically, as you wish to return to, I have not jumped into anything, except apparently your face. I believe that the past history of Wellcome's misbehavior, and Gallo should be enough to make any information that you provide concerning AZT and/or HIV suspect. If the basics are flawed, which I BELIEVE that they are, the rest should and must be. You're a data miner. Need me to explain that one? jb > >Carlton From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!news-a.ais.net!ais.net!newshub.tc.umn.edu!news1.tc.umn.edu!walleye.ccbr.umn.edu!carlton From: carlton@walleye.ccbr.umn.edu (Carlton Hogan) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 5 Oct 1998 15:49:36 GMT Organization: Department of Biostatistics, University of Minnesota Lines: 31 Message-ID: <6vapqg$e07$1@news1.tc.umn.edu> References: <6tm101$9p8$4@nnrp02.primenet.com> <36155a63.88553199@netnews.worldnet.att.net> <6v55as$8t4$1@nnrp1.dejanews.com> <361669aa.158010084@netnews.worldnet.att.net> NNTP-Posting-Host: walleye.ccbr.umn.edu Xref: biosci bionet.immunology:14826 bionet.molbio.hiv:4982 In article <361669aa.158010084@netnews.worldnet.att.net>, wrote: >On Sat, 03 Oct 1998 12:29:21 GMT, f.raaphorst@worldonline.nl wrote: > >>> >> The short answer or the long one? I prefer the short. Less AZT >>> >> combined with anything else in the PI category means less toxicity. >>> >> Why is that so confusing? Am I missing something, do you contend that >>> >> the same amounts of AZT are given "with" PI "therapy" as "recommended" >>> >> alone? There you have it, a "dissident "explains".jb >>> > >>> >Thanks for this testimony of ignorance. I'll give you a chance to correct >>> >it though. Please post data showing that AZT in combo therapy is given in >>> >lower doses than used in monotherapy. If those data show the doses are no >>> >different, then please address the question again. >>> Marnix, people are living longer without the dosages of AZT as before >>> the era of the PI's for "AIDS" therapy. Just check out the declining >>> death rates, your choice, CDC, NIH, whatever. Answer the question, >>> are AZT dosages less in combined therapy than when AZT was prescribed >>> alone? Can't handle this one, Herr Marnix? jb >> >>Just answer the question jb, not this evasive stuff. >>Come on, we're waiting. >you first. It's the same kind of question, a trap. All you have to >do is answer "yes or no". jb The answer is "no", AZT is not generally prescribed in reduced dosage with PIs. FDA approval, package inserts, and "expert panels", like the IoMs and the IAS's all concur. Come back when you know something. Carlton From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!news-a.ais.net!ais.net!newshub.tc.umn.edu!news1.tc.umn.edu!walleye.ccbr.umn.edu!carlton From: carlton@walleye.ccbr.umn.edu (Carlton Hogan) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 5 Oct 1998 15:54:20 GMT Organization: Department of Biostatistics, University of Minnesota Lines: 35 Message-ID: <6vaq3c$enb$1@news1.tc.umn.edu> References: <6tm101$9p8$4@nnrp02.primenet.com> <6v621u$2a8$1@nnrp1.dejanews.com> <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> <3617f386.29105757@netnews.worldnet.att.net> NNTP-Posting-Host: walleye.ccbr.umn.edu Xref: biosci bionet.immunology:14827 bionet.molbio.hiv:4983 In article <3617f386.29105757@netnews.worldnet.att.net>, wrote: >On Sun, 04 Oct 1998 19:51:51 GMT, gmc0@ix.netcom.com (George M. >Carter) wrote: > >>f.raaphorst@worldonline.nl wrote: >> >>>In article <6v5q3u$98j@sjx-ixn10.ix.netcom.com>, >>> gmc0@ix.netcom.com wrote: >>>> johnburgin@worldnet.att.net wrote: >>>> >> >>>> Hey dipshit!! Get a clue!! The dose of AZT started at 1200 mg. Way >>>> too much. People died at that dose. It was cut to 600 mg very >>>> quickly. This was in the late 80s early 90s. That was the >>>> monotherapy dose. (300 mg probably works as well). >Why not use 300 then? Because of resistance concerns: in vitro work suggests that "trough" levels are too low to guarantee continued suppression, although there has not ben clinical endpoint trials over a long enough duration to confirm it. > The reality is, > >that you still haven't answered my question. What is the dosage with >PI's? 600? That's 600mg too much. OK, let's take this thread back to it's beginning. I have answered your question. Now you explain why, if AZT is so toxic and non-beneficial, is a survival benefit seen for AZT + *another* nuke + PI? Put up or shut up. Carlton From owner-immunology@net.bio.net Sun Oct 04 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!howland.erols.net!wn3feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 5 Oct 1998 21:43:10 GMT Organization: AT&T WorldNet Services Lines: 73 Message-ID: <36193c02.113210495@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v5q3u$98j@sjx-ixn10.ix.netcom.com> <6v621u$2a8$1@nnrp1.dejanews.com> <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> <3617f386.29105757@netnews.worldnet.att.net> <6vapc0$s24@sjx-ixn1.ix.netcom.com> NNTP-Posting-Host: 12.65.211.188 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14831 bionet.molbio.hiv:4989 On Mon, 05 Oct 1998 15:44:55 GMT, gmc0@ix.netcom.com (George M. Carter) wrote: >johnburgin@worldnet.att.net wrote: > >>On Sun, 04 Oct 1998 19:51:51 GMT, gmc0@ix.netcom.com (George M. >>Carter) wrote: > >>>f.raaphorst@worldonline.nl wrote: >>> >>>>In article <6v5q3u$98j@sjx-ixn10.ix.netcom.com>, >>>> gmc0@ix.netcom.com wrote: >>>>> johnburgin@worldnet.att.net wrote: >>>>> >>> >>>>> Hey dipshit!! Get a clue!! The dose of AZT started at 1200 mg. Way >>>>> too much. People died at that dose. It was cut to 600 mg very >>>>> quickly. This was in the late 80s early 90s. That was the >>>>> monotherapy dose. (300 mg probably works as well). >\ >>Why not use 300 then? > >Good question! But they don't. > >> The reality is, > >>that you still haven't answered my question. What is the dosage with >>PI's? 600? That's 600mg too much. > >They use 600. Can't you read?? Well, asshole, this completely >contradicts your lame assertion that people aren't dropping dead of >"AZT induced AIDS" because the dosage is less. It's not. And who says they're not dropping dead a little slower, which is my contention? Who can tell the difference between a slow death with AZT and PI's and AIDS? Why do you keep defending a bad drug? > >>>>> though, people today are STILL taking 600 mg a day. Same dose. >>>>> >>>>> So you're just fucking dead cold wrong and dumb as a post. >>Now you're trying to hurt my feelings again by using your extended >>vocabulary(remember, a long time ago we spoke of this, after your >>maxim of 100 usable words you start using profanity). > >Your feelings SHOULD be hurt. You're spreading idiocy and >misinformation that could KILL people. You don't like my vocabulary, >well tough titties. Now you're telling me how I should feel. Boy, that's really getting low. My "misinformation" will only cause people to read more about alternatives that they have not explored. If they at the very least look into HEAL, they will do nothing more to themselves than have another viewpoint. If they start with your lunacy, jumping on the drugs, they'll be sick or dead in most cases depending on who is still recommending AZT, like you. > >> And you >>>>> claim to be in the medical field. > >>No claim, I am, and you're not. > >Then god help the medical community. Say--where are you? > >Now: face it. You fucked up big time again. As a member of the >medical community, why didn't you bother to find out that people are >taking the same (600 mg) dose of AZT? You wouldn't have made such a >great wanking fool out of yourself. George, a "wanking" fool? Not in my dictionary. I still repeat, 600mg is 600 too much without supportive data, which is still wanking. jb > > George M. Carter > > From owner-immunology@net.bio.net Mon Oct 05 23:00:00 1998 Message-ID: <3619D163.61E@jps.net> Date: Tue, 06 Oct 1998 01:14:27 -0700 From: "Charles P. McCarthy, P.M.D. (Hon)" Reply-To: Pandoc@jps.net Organization: Bio International X-Mailer: Mozilla 3.01Gold (Win16; I) MIME-Version: 1.0 Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: HIV/AIDS and the Perth Group. Was:"AIDS Treatment News"... References: <6tm101$9p8$4@nnrp02.primenet.com> <6ubd93$sp9$1@news1.tc.umn.edu> <36096dc3.149849333@netnews.worldnet.att.net> <6ue2ve$95g$1@news1.tc.umn.edu> <360acf8a.240430063@netnews.worldnet.att.net> <360bf798.316232381@netnews.worldnet.att.net> <6un1ub$7la$1@nnrp1.dejanews.com> Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit NNTP-Posting-Host: 209.239.197.208 X-NNTP-Posting-Host: 209.239.197.208 Lines: 11 X-NNTP-Posting-Host: 209.63.114.134 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.cwix.com!207.0.56.122!news.eli.net!blushng.jps.net!209.239.197.208 Xref: biosci bionet.immunology:14835 bionet.molbio.hiv:4994 ROBERT S. HOLZMAN wrote: > The principle you seem to be missing is you don't need pure antgens to produce > antibodies. > > Nor do you need pure antigens to measure the antibodies, although it helps. When talking to todd or other recalcitrant nincompoops, you should probably speak in purified yiddish... Rabbidoc From owner-immunology@net.bio.net Mon Oct 05 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!news.eecs.umich.edu!newshub.tc.umn.edu!news1.tc.umn.edu!walleye.ccbr.umn.edu!carlton From: carlton@walleye.ccbr.umn.edu (Carlton Hogan) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 6 Oct 1998 18:35:42 GMT Organization: Department of Biostatistics, University of Minnesota Lines: 56 Message-ID: <6vdntu$2fd$1@news1.tc.umn.edu> References: <6tm101$9p8$4@nnrp02.primenet.com> <3617f386.29105757@netnews.worldnet.att.net> <6vapc0$s24@sjx-ixn <36193c02.113210495@netnews.worldnet.att.net> NNTP-Posting-Host: walleye.ccbr.umn.edu Xref: biosci bionet.immunology:14840 bionet.molbio.hiv:4995 In article <36193c02.113210495@netnews.worldnet.att.net>, wrote: >On Mon, 05 Oct 1998 15:44:55 GMT, gmc0@ix.netcom.com (George M. >Carter) wrote: (snip)> >>> The reality is, >> >>>that you still haven't answered my question. What is the dosage with >>>PI's? 600? That's 600mg too much. >> >>They use 600. Can't you read?? Well, asshole, this completely >>contradicts your lame assertion that people aren't dropping dead of >>"AZT induced AIDS" because the dosage is less. It's not. >And who says they're not dropping dead a little slower, which is my >contention? Who can tell the difference between a slow death with AZT >and PI's and AIDS? Why do you keep defending a bad drug? You still haven't explain why there is marked survival benefit for AZT in combination with ANOTHER nuke + PI compared to AZT alone. If AZT and AZT-like drugs were so toxic, we would expect the exact opposite. (Snip) >> >>Now: face it. You fucked up big time again. As a member of the >>medical community, why didn't you bother to find out that people are >>taking the same (600 mg) dose of AZT? You wouldn't have made such a >>great wanking fool out of yourself. >George, a "wanking" fool? Not in my dictionary. I still repeat, >600mg is 600 too much without supportive data, which is still wanking. OK. You claim that the supporting data is not there. Please then offer meaningful and detailed criticisms of ACTG 320, Abbott 047, the CAESAR trial, and the original Erons et al AZT+3tc study. These are but a few in the literally dozens of trials looking at combination nukes. While you are at it, howabout EACG 017, and the VA cooperative trial? You claim that there is no supporting data: I claim that you are not even minimally familiar with the literature. If you feel these trials are in error, please list specific flaws, not just the fact that they contradict your preconceptions. Carlton __________________________________________________________________________ | | | Carlton Hogan (carlton@gopher.ccbr.umn.edu) | | Community Programs for Clinical Research on AIDS Statistical Center | | Coordinating Center for Biometric Research | | Division of Biostatistics, School of Public Health | | University of Minnesota http://www.biostat.umn.edu/~carlton | | 2221 University Ave SE, Suite 200 Voice: (612) 626 8899 | | Minneapolis MN 55414 FAX: (612) 626 8892 | |________________________________________________________________________| Affilation provided for purpose of identification, not representation. From owner-immunology@net.bio.net Mon Oct 05 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Ilya Trakht Newsgroups: bionet.immunology Subject: Postdoctoral Position - Columbia University Date: 6 Oct 1998 11:37:23 -0700 Organization: Columbia University Lines: 27 Sender: daemon@net.bio.net Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net Postdoctoral Position available now for recent graduates trained in cell biology, molecular biology and immunology, with interests in developing totally human monoclonal antibodies to cancer-associated antigens and infectious agents with a potential for application in clinical medicine. An extensive expetise in cell culture, immunoassays, immunohistochemistry, molecular biology techniques is mostly preferred. Interested individuals should forward Curriculum Vitae, description research experience, brief statement of research interests and three letters of recomendation to: Dr. Ilya Trakht Department of Medicine, Columbia University 650W, 168th Street, BB-1011 New York, NY 10032 E-mail: it8@columbia.edu From owner-immunology@net.bio.net Mon Oct 05 23:00:00 1998 Path: biosci!PANGAEA-PHARM.COM!gcole From: gcole@PANGAEA-PHARM.COM (Geoffery Cole) Newsgroups: bionet.immunology Subject: x-, versus gamma-irradiation to prepare human PBL as stimulator cells Date: 6 Oct 1998 05:32:31 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 12 Sender: daemon@net.bio.net Distribution: world Message-ID: <01BDF104.B8DD0E60@optiplex.III.pangaea-pharm.com> NNTP-Posting-Host: net.bio.net I'm seeking feedback as to whether x-ray irradiation, rather than gamma-irradiation, is used to prepare PBL stimulator cells for in vitro CTL cultures. Purchase of an x-ray generating unit, as opposed to an irradiator with a sealed gamma source, is less costly and engenders fewer regulatory and safety issues. I know of one company (Associated X-Ray Corp in East Haven, CT) which makes a suitable machine. In fact, I used one of their units in years past when doing mouse T cell culture work. However, I've never seen any investigator report in the literature that they prepared autologous stimulators for CD8+ T cell cultures by x-irradiation. Comments by anyone who does human T-cell culture work would be appreciated. Thanks. Geoffrey Cole From owner-immunology@net.bio.net Mon Oct 05 23:00:00 1998 Path: biosci!ihnp4.ucsd.edu!awabi.library.ucla.edu!208.134.241.18!newsfeed.cwix.com!198.138.0.5!newshub.northeast.verio.net!news-xfer.netaxs.com!newsread.com!news.okstate.edu!not-for-mail From: pjoseph@osucom-fs02.ocom.okstate.edu (Joseph A. Price, Ph.D.) Newsgroups: bionet.immunology,sci.med.immunology Subject: Re: Question about allergic reactions. Date: 6 Oct 1998 17:07:30 GMT Organization: OSU-COM Lines: 25 Message-ID: <6vdioi$b2u21@news.cis.okstate.edu> References: NNTP-Posting-Host: 139.78.232.105 Mime-Version: 1.0 Content-Type: Text/Plain; charset=US-ASCII X-Newsreader: WinVN 0.99.9 (Released Version) (x86 32bit) In article , sanyal@home.com says... > >I am very allergic to cats, ... > >When I returned to Canada, I was surprised that I did not display any >allergic symptoms when I was exposed to cats. >However, it has now been 6 months since I returned and I have begun to >redisplay the exact same symptoms again, It is most likely that your immune response to cat allergns waned without regular stimulation while you were abroad. Thus you were unreactive or subclinically reactive when you first returned. After enough reexposure and time, your immune responses to cat allergen were rekindled, and your problems returned. Dept. Bioch. & Microbiol., OSU-COM 1111 W. 17th. St., Tulsa OK 74107 Ph. 918-561-8231 FAX 918-561-8414 pjoseph@osucom-fs02.ocom.okstate.edu http://osu.com.okstate.edu/dept/basic/bio_micro/jprice.htm From owner-immunology@net.bio.net Mon Oct 05 23:00:00 1998 Path: biosci!news.stanford.edu!su-news-feed2.bbnplanet.com!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.wli.net!howland.erols.net!newspeer.monmouth.com!news.eecs.umich.edu!newshub.tc.umn.edu!news1.tc.umn.edu!walleye.ccbr.umn.edu!carlton From: carlton@walleye.ccbr.umn.edu (Carlton Hogan) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 6 Oct 1998 18:41:59 GMT Organization: Department of Biostatistics, University of Minnesota Lines: 34 Message-ID: <6vdo9n$34p$1@news1.tc.umn.edu> References: <6tm101$9p8$4@nnrp02.primenet.com> <3617f386.29105757@netnews.worldnet.att.net> <6vaq3c$enb$1@news1.tc.umn.edu> <36193d76.113582531@netnews.worldnet.att.net> NNTP-Posting-Host: walleye.ccbr.umn.edu Xref: biosci bionet.immunology:14841 bionet.molbio.hiv:4996 In article <36193d76.113582531@netnews.worldnet.att.net>, wrote: >On 5 Oct 1998 15:54:20 GMT, carlton@walleye.ccbr.umn.edu (Carlton >Hogan) wrote: > >> >>OK, let's take this thread back to it's beginning. I have answered your >>question. Now you explain why, if AZT is so toxic and non-beneficial, >>is a survival benefit seen for AZT + *another* nuke + PI? >>Put up or shut up. >I don't have to do any such thing. Remember, this is the internet, >cyberspace, we, all of us, can have and express an opinion. You were >given a nice diatribe by Todd Miller, whom you readily dismissed as >les incompetent. Why should I expect any different treatment from >you. Not all are seeing the "survival benefit" from AZT +*another* >nuke + PI. That's still up for debate. Again, I would suggest that you demonstrate the specific flaws in the dozen or so clinical trials that have shown an AIDS-free survival benefit to combination therapy. Todd posted on a molecular biology concern, not a clinical one, having to do with phosphorylation of AZT. What he probably didn't realize when he posted it is that arguing that little or no AZT gets phosphorylated pretty much junks any statements about AZT being a terminater of host DNA. If not enough gets phosphorylated to interfere with RT, then given the relative specificity of AZT, even less is available for interfering with host DNA synthesis. Perhaps you should get a basic familiarity with the field: it would save you from these embarassing revelations of your ignorance. If you like, I can refer you to some basic texts. Carlton From owner-immunology@net.bio.net Mon Oct 05 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Ilya Trakht Newsgroups: bionet.immunology Subject: Staff Associate - Columbia University Date: 6 Oct 1998 11:37:17 -0700 Organization: Columbia University Lines: 25 Sender: daemon@net.bio.net Distribution: world Message-ID: NNTP-Posting-Host: net.bio.net Staff Associate position available to study the repertoire of human antibodies to cancer-associated antigens and infectious agents. The ongoing project is dealing with the development of totally human monoclonal antibodies using hybridoma methodology and lymph tissues from human subjects. The application of such antibodies in clinical medicine is an ultimate goal of the project. Position requires a degree in biological science and knowledge in this field. Candidates with extensive experience in cell biology, molecular biology, immunohistochemistry and immunology are encouraged to send their curriculum vitae and three references to: Ilya Trakht, Ph.D. Department of Medicine, Columbia University 630 W 168 Street BB-1011 New York NY 10032 E-mail: it8@columbia.edu From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!CS.Arizona.EDU!math.arizona.edu!noao!ncar!newsxfer.itd.umich.edu!nntp.cs.ubc.ca!newsfeed.direct.ca!torn!kwon!watserv3.uwaterloo.ca!not-for-mail From: Phil Caskanette Newsgroups: bionet.immunology,sci.med.immunology Subject: Re: Question about allergic reactions. Date: Tue, 06 Oct 1998 14:18:31 -0400 Organization: Univ. of Waterloo Lines: 39 Message-ID: <361A5EF7.2B50@mc1adm.uwaterloo.ca> References: <6vdioi$b2u21@news.cis.okstate.edu> Reply-To: caskanet@UWaterloo.ca NNTP-Posting-Host: iapc3.uwaterloo.ca Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Mailer: Mozilla 3.0Gold (Win95; I) Joseph A. Price, Ph.D. wrote: > > In article , sanyal@home.com > says... > > > >I am very allergic to cats, ... > > > >When I returned to Canada, I was surprised that I did not display any > >allergic symptoms when I was exposed to cats. > > >However, it has now been 6 months since I returned and I have begun to > >redisplay the exact same symptoms again, > > It is most likely that your immune response to cat allergns waned without > regular stimulation while you were abroad. Thus you were unreactive or > subclinically reactive when you first returned. After enough reexposure and > time, your immune responses to cat allergen were rekindled, and your problems > returned. That sounds right based on my experience, and my allergists' explanations. I don't think a 'clean environment' has anything to do with the phenomonen experienced by Steve. My allergists said it was dependent on whether you went somewhere that had sufficiently different allergens from your normal environment. I spent 2 years in Northern Alberta and at first my allergies waned. Then I developed allergies to native plants in the region. I thought it was a cold that wouldn't go away, but it was allergies. When I moved back to Ontario, my allergic reactions waned and I felt fine for about 6 months. Then the cycle started again. -- ======================================================================= Phil Caskanette | e-mail: caskanet@UWaterloo.ca Senior Auditor | phone: (519) 888-4567 x2774 University of Waterloo | fax: Waterloo, Ont., Canada N2L 3G1 | ======================================================================= Disclaimer: All expressed opinions are mine, and are not necessarily the views of my employer. From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!news.alaska.edu!newsfeed.acns.nwu.edu!newsfeed.berkeley.edu!newsfeed.cwix.com!204.238.120.130!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: govind_pgi@yahoo.com Newsgroups: bionet.immunology Subject: Re: PHA action mode help Date: Wed, 07 Oct 1998 11:37:43 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 30 Message-ID: <6vfjq7$n4u$1@nnrp1.dejanews.com> References: <6velhs$pr2$1@nnrp1.dejanews.com> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Wed Oct 07 11:37:43 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x4.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 In article <6velhs$pr2$1@nnrp1.dejanews.com>, strider@comteco.entelnet.bo wrote: > Hello, can anybody tell me how the PHA works in the PBMC? > I'm in Bolivia, and it's close to imposible for me to use > such tools as medline... > > Thanx 4 your help > > Cristina Alonso-Vega Hello there, PHA is a lectin, means it binds to some sugar residues. Most probably it binds some sugar residues attached to certain molecules on T cells and it cross links those molecules. This transduces activation signals to T cells. The important point is that presence of antigen presenting cells is important. This is as for as I know. Good luck Govind > > ps please send me e-mail > > -----------== Posted via Deja News, The Discussion Network ==---------- > http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own > -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!CS.Arizona.EDU!noao!math.arizona.edu!news.Arizona.EDU!uunet!in5.uu.net!news.new-york.net!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!wn3feed!worldnet.att.net!135.173.83.225!attworldnet!newsadm From: johnburgin@worldnet.att.net Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 8 Oct 1998 03:31:30 GMT Organization: AT&T WorldNet Services Lines: 25 Message-ID: <361c31dd.121102119@netnews.worldnet.att.net> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v5q3u$98j@sjx-ixn10.ix.netcom.com> <6v621u$2a8$1@nnrp1.dejanews.com> <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> <3617f386.29105757@netnews.worldnet.att.net> <6vapc0$s24@sjx-ixn1.ix.netcom.com> <36193c02.113210495@netnews.worldnet.att.net> <6vga2c$2vu@dfw-ixnews8.ix.netcom.com> NNTP-Posting-Host: 12.65.211.224 X-Newsreader: Forte Free Agent 1.11/32.235 Xref: biosci bionet.immunology:14850 bionet.molbio.hiv:5000 On Wed, 07 Oct 1998 18:00:36 GMT, gmc0@ix.netcom.com (George M. Carter) wrote: > >SNip... >Me.>> >>>They use 600. Can't you read?? Well, asshole, this completely >>>contradicts your lame assertion that people aren't dropping dead of >>>"AZT induced AIDS" because the dosage is less. It's not. > >The dentist: >>And who says they're not dropping dead a little slower, which is my >>contention? Who can tell the difference between a slow death with AZT >>and PI's and AIDS? Why do you keep defending a bad drug? > >Well, that makes a lot of sense. If "drugs cause AIDS" then lets add >MORE toxic drugs to the mix and people will die more slowly. If you're the first, sounds good to me. jb > >Your logic is devastating. > > George M. Carter > > From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!webtv.net!newsfeed.concentric.net!howland.erols.net!newsfeed.cwix.com!204.238.120.130!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: strider@comteco.entelnet.bo Newsgroups: bionet.immunology Subject: PHA action mode help Date: Wed, 07 Oct 1998 03:01:16 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 12 Message-ID: <6velhs$pr2$1@nnrp1.dejanews.com> NNTP-Posting-Host: 166.114.103.230 X-Article-Creation-Date: Wed Oct 07 03:01:16 1998 GMT X-Http-User-Agent: Mozilla/4.0 (compatible; MSIE 4.01; Windows 98) X-Http-Proxy: 1.1 x2.dejanews.com:80 (Squid/1.1.22) for client 166.114.103.230 Hello, can anybody tell me how the PHA works in the PBMC? I'm in Bolivia, and it's close to imposible for me to use such tools as medline... Thanx 4 your help Cristina Alonso-Vega ps please send me e-mail -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!news.alaska.edu!newsfeed.acns.nwu.edu!news-spur1.maxwell.syr.edu!news.maxwell.syr.edu!howland.erols.net!torn!nott!cunews!wabakimi!astewar2 From: astewar2@chat.carleton.ca (Andy Stewart) Newsgroups: bionet.immunology Subject: New Job Board / Skills Database for Hitech/Biotech Date: 7 Oct 1998 18:18:29 GMT Organization: Carleton University, Ottawa, Canada Lines: 7 Message-ID: <6vgb9l$f2j$1@bertrand.ccs.carleton.ca> NNTP-Posting-Host: wabakimi.carleton.ca NNTP-Posting-User: astewar2 X-Newsreader: TIN [version 1.2 PL2] Check out Biotech Networks new biotech resource. The site offers free job board access, resume posting and consolidated biotech resources. Check out this invaluable resource at http://www.bionet.on.ca. From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!webtv.net!newsfeed.concentric.net!feed1.news.rcn.net!rcn!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!rill.news.pipex.net!pipex!server1.netnews.ja.net!news.nott.ac.uk!wmbcdg2.nottingham.ac.uk!user From: andrew.devitt@nottingham.ac.uk (Chut) Newsgroups: bionet.immunology Subject: IL-14 Date: Thu, 08 Oct 1998 18:11:51 +0000 Organization: The University of Nottingham Lines: 7 Message-ID: NNTP-Posting-Host: wmbcdg2.nottingham.ac.uk Does anyone know of a supplier for IL-14. Preferably in the UK or from a company with a UK supplier. Many thanks Andrew Please reply to: andrew.devitt@nottingham.ac.uk From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!webtv.net!newsfeed.concentric.net!howland.erols.net!ix.netcom.com!news From: "Scott Shanes" Newsgroups: bionet.immunology Subject: US-CA-RESEARCH ASSOCIATE MOLECULAR BIOLOGY Date: Wed, 7 Oct 1998 17:28:16 -0000 Organization: ICGNetcom Lines: 16 Message-ID: <6vgme2$seu@dfw-ixnews5.ix.netcom.com> NNTP-Posting-Host: trn-nj1-22.ix.netcom.com X-NETCOM-Date: Wed Oct 07 4:28:34 PM CDT 1998 X-Newsreader: Microsoft Outlook Express 4.71.1712.3 X-MimeOLE: Produced By Microsoft MimeOLE V4.71.1712.3 I am looking for a person to work in a lab that is identifying secreted proteins used as therapeutic drug targets. You will utilize molecular biology skills to perform Cloning, Plasmid and Phage Preparation, PCR, making CDNA Libraries, Library Screening, Southern and Northern Blot Analyses, Western Blotting, etc. Good communication and organizational skills are a plus. The candidate should possess a B.S., M.S. or MD degree. Our client is a leading bio-tech company with research facilities in Central California and can provide excellent benefits (health insurance, dental, and vision plan, paid vacation and more). A high impact, high profile position with excellent opportunity for advancement. Please contact Scott Shanes by phone at 609-584-8733 Ext. 218, fax resume and cover letter to 609-584-9575 or E-Mail to sis@diedremoire.com From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!webtv.net!su-news-feed4.bbnplanet.com!su-news-hub1.bbnplanet.com!cpk-news-hub1.bbnplanet.com!news.bbnplanet.com!netnews.com!news-b.ais.net!ais.net!newshub.tc.umn.edu!news1.tc.umn.edu!walleye.ccbr.umn.edu!carlton From: carlton@walleye.ccbr.umn.edu (Carlton Hogan) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: 8 Oct 1998 17:01:34 GMT Organization: Department of Biostatistics, University of Minnesota Lines: 31 Message-ID: <6vir5e$kdo$1@news1.tc.umn.edu> References: <6tm101$9p8$4@nnrp02.primenet.com> <3617f386.29105757@netnews.worldnet.att.net> <6vapc0$s24@sjx-ixn <361c31dd.121102119@netnews.worldnet.att.net> NNTP-Posting-Host: walleye.ccbr.umn.edu Xref: biosci bionet.immunology:14852 bionet.molbio.hiv:5001 In article <361c31dd.121102119@netnews.worldnet.att.net>, wrote: >On Wed, 07 Oct 1998 18:00:36 GMT, gmc0@ix.netcom.com (George M. >Carter) wrote: > >> >>SNip... >>Me.>> >>>>They use 600. Can't you read?? Well, asshole, this completely >>>>contradicts your lame assertion that people aren't dropping dead of >>>>"AZT induced AIDS" because the dosage is less. It's not. >> >>The dentist: >>>And who says they're not dropping dead a little slower, which is my >>>contention? Who can tell the difference between a slow death with AZT >>>and PI's and AIDS? Why do you keep defending a bad drug? >> >>Well, that makes a lot of sense. If "drugs cause AIDS" then lets add >>MORE toxic drugs to the mix and people will die more slowly. > If you're the first, sounds good to me. jb Does this mean that you have absolutely no intelligent response, and are unable to marshal any facts in this argument so you are resorting to personal attack? Brilliant strategy. Helps to confirm your stunning critical insight, and command of the literature. Wanker. (by the way, genius boy: you just said you would like George to be the first to die more slowly - I am sure he is all choked up by your warm sentiment) Carlton From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!webtv.net!newsfeed.concentric.net!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.berkeley.edu!newsfeed.cwix.com!204.238.120.130!news-feeds.jump.net!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: da_bruva@hotmail.com Newsgroups: bionet.immunology Subject: dentritic cells Date: Thu, 08 Oct 1998 06:43:23 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 10 Message-ID: <6vhmub$grt$1@nnrp1.dejanews.com> NNTP-Posting-Host: 130.34.170.137 X-Article-Creation-Date: Thu Oct 08 06:43:23 1998 GMT X-Http-User-Agent: Mozilla/3.02 (Macintosh; I; PPC) X-Http-Proxy: 1.0 x12.dejanews.com:80 (Squid/1.1.22) for client 130.34.170.137 Can anyone assist me with a clear protocol on purifing mouse dendritics using 50% Percoll gradient....what exactly is 50% percoll gradients etc much appreciated Dave -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!news.stanford.edu!Cabal.CESspool!bofh.vszbr.cz!newsfeed.wli.net!howland.erols.net!ix.netcom.com!news From: gmc0@ix.netcom.com (George M. Carter) Newsgroups: bionet.immunology,bionet.molbio.hiv,uk.people.health Subject: Re: "AIDS Treatment News" online * New Issue #302 (searchable/indexed) Date: Wed, 07 Oct 1998 18:00:36 GMT Organization: Free Radical Enterprises Lines: 20 Message-ID: <6vga2c$2vu@dfw-ixnews8.ix.netcom.com> References: <6tm101$9p8$4@nnrp02.primenet.com> <360c04a9.319577014@netnews.worldnet.att.net> <6uoekt$e45$1@news1.tc.umn.edu> <3611441e.663553911@netnews.worldnet.att.net> <6v0dag$j5k$1@news1.tc.umn.edu> <361545cd.83282293@netnews.worldnet.att.net> <36155a63.88553199@netnews.worldnet.att.net> <6v5q3u$98j@sjx-ixn10.ix.netcom.com> <6v621u$2a8$1@nnrp1.dejanews.com> <6v8jf1$obf@dfw-ixnews5.ix.netcom.com> <3617f386.29105757@netnews.worldnet.att.net> <6vapc0$s24@sjx-ixn1.ix.netcom.com> <36193c02.113210495@netnews.worldnet.att.net> Reply-To: gmc0@ix.netcom.com NNTP-Posting-Host: nyc-ny91-31.ix.netcom.com X-NETCOM-Date: Wed Oct 07 12:57:32 PM CDT 1998 X-Newsreader: Forte Free Agent 1.0.82 Xref: biosci bionet.immunology:14847 bionet.molbio.hiv:4999 SNip... Me.>> >>They use 600. Can't you read?? Well, asshole, this completely >>contradicts your lame assertion that people aren't dropping dead of >>"AZT induced AIDS" because the dosage is less. It's not. The dentist: >And who says they're not dropping dead a little slower, which is my >contention? Who can tell the difference between a slow death with AZT >and PI's and AIDS? Why do you keep defending a bad drug? Well, that makes a lot of sense. If "drugs cause AIDS" then lets add MORE toxic drugs to the mix and people will die more slowly. Your logic is devastating. George M. Carter From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!webtv.net!newsfeed.concentric.net!su-news-hub1.bbnplanet.com!news.bbnplanet.com!newsfeed.berkeley.edu!news.stanford.edu!nntp.stanford.edu!not-for-mail From: robinb@leland.Stanford.EDU (Robin Blumenthal) Newsgroups: bionet.immunology Subject: Competitive PCR Date: 8 Oct 1998 17:27:48 GMT Lines: 21 Message-ID: <6vismk$5oo$1@nntp.Stanford.EDU> NNTP-Posting-Host: elaine2.stanford.edu X-Newsreader: TIN [UNIX 1.3 950824BETA PL0] Does anyone know of a company which sells kits or products to do competitive PCR- specifically I am looking for human interleukins including IL-13 I would very much appreciate any information. Thank you. Robin Blumenthal -- ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Robin Blumenthal, Ph.D. Department of Pediatrics, Rm S303 Stanford University 300 Pasteur Drive Stanford, California 94305 robinb@leland.stanford.edu (650) 723-8224 (650) 498-4632 FAX ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!news.alaska.edu!newsfeed.acns.nwu.edu!newsfeed.berkeley.edu!newsfeed.enteract.com!netnews.com!newspeer.monmouth.com!nntp2.dejanews.com!nnrp1.dejanews.com!not-for-mail From: govind_pgi@yahoo.com Newsgroups: bionet.immunology Subject: transfection Date: Wed, 07 Oct 1998 13:09:40 GMT Organization: Deja News - The Leader in Internet Discussion Lines: 13 Message-ID: <6vfp6j$vik$1@nnrp1.dejanews.com> NNTP-Posting-Host: 202.54.56.36 X-Article-Creation-Date: Wed Oct 07 13:09:40 1998 GMT X-Http-User-Agent: Mozilla/4.06 [en] (Win95; I) X-Http-Proxy: 1.0 charak.sgpgi.ac.in:8080 (Squid/1.1.21), 1.0 x8.dejanews.com:80 (Squid/1.1.22) for client 192.100.10.239, 202.54.56.36 HEllo friends, I am interested in ttransfecting adherent cells (liver cells) by calcium phosphate mediated transfection. I want to know the protocol for transfecting in 24 well or 6 well plates. The details like amount of DNA and volume of the transfection solution are requested. Thanks in advance Govind -----------== Posted via Deja News, The Discussion Network ==---------- http://www.dejanews.com/ Search, Read, Discuss, or Start Your Own From owner-immunology@net.bio.net Wed Oct 07 23:00:00 1998 Path: biosci!news.alaska.edu!newsfeed.acns.nwu.edu!newsfeed.berkeley.edu!newsfeed1.swip.net!swipnet!rill.news.pipex.net!pipex!dispose.news.demon.net!demon!peer.news.zetnet.net!zetnet.co.uk!user From: nigel.osborn@zetnet.co.uk (Nigel J.Osborn) Newsgroups: bionet.immunology Subject: Integration software for FPLC Date: Wed, 07 Oct 1998 18:23:21 +0100 Organization: Amersham, Bucks Message-ID: NNTP-Posting-Host: man-089.dialup.zetnet.co.uk X-Trace: irk.zetnet.co.uk 907780958 19371 194.247.41.111 (7 Oct 1998 17:22:38 GMT) NNTP-Posting-Date: 7 Oct 1998 17:22:38 GMT Lines: 10 Does anyone know of any integration software available for FPLC? Ideally I would like to be able to scan in a chromatogram and get it to tell me peak areas and relative peak areas. Preferably shareware though commercial products also would probably be O.K. Nigel Osborn. From owner-immunology@net.bio.net Thu Oct 08 23:00:00 1998 Path: biosci!cica.es!alvarez From: alvarez@cica.es (Jose Santos Alvarez) Newsgroups: bionet.immunology Subject: Flow cytometry of adhere